

# Prevention and Control of Meningococcal Disease

## Recommendations of the Advisory Committee on Immunization Practices (ACIP)



Continuing Education Examination available at <http://www.cdc.gov/mmwr/cme/conted.html>.



**U.S. Department of Health and Human Services**  
Centers for Disease Control and Prevention

## CONTENTS

Introduction .....	1
Methods.....	2
Background .....	4
Meningococcal Vaccines.....	7
Postlicensure Safety Surveillance for Meningococcal Conjugate Vaccines .....	11
Cost-Effectiveness Analyses .....	13
Rationale for Recommendations for Use of Meningococcal Vaccines .....	13
Recommendations for Use of Meningococcal Vaccines .....	14
Future Meningococcal Vaccines, Areas for Research, and Public Education.....	18
References.....	19
APPENDIX A.....	23
APPENDIX B.....	25

## CDC Adoption of ACIP Recommendations

ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of the Centers for Disease Control and Prevention (CDC) on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of the United States. Recommendations for routine use of vaccines in children and adolescents are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists. Recommendations for routine use of vaccines in adults are reviewed and approved by the American College of Physicians (ACP), AAFP, the American College of Obstetricians and Gynecologists, and the American College of Nurse-Midwives. ACIP recommendations adopted by the CDC Director become agency guidelines on the date published in the *Morbidity and Mortality Weekly Report (MMWR)*.

## Disclosure of Relationship

CDC, our planners, and our content experts wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. This report includes discussion of the unlabeled use of meningococcal vaccines in the following situations:

1. Meningococcal conjugate vaccines are licensed only as a single dose. The 2-dose series of meningococcal conjugate vaccine is recommended for persons with certain medical risk factors, and the booster dose of meningococcal conjugate vaccine is recommended for adolescents and persons who remain at increased risk for a prolonged period.
2. Persons aged  $\geq 56$  years who have been vaccinated previously with MenACWY are recommended to receive a booster dose of MenACWY as indicated.

The *MMWR* series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Title]. *MMWR* 2013;62(No. RR-#):[inclusive page numbers].

### Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH, *Director*  
 Harold W. Jaffe, MD, MA, *Associate Director for Science*  
 James W. Stephens, PhD, *Director, Office of Science Quality*  
 Denise M. Cardo, MD, *Acting Deputy Director for Surveillance, Epidemiology, and Laboratory Services*  
 Stephanie Zaza, MD, MPH, *Director, Epidemiology and Analysis Program Office*

### MMWR Editorial and Production Staff

Ronald L. Moolenaar, MD, MPH, <i>Editor, MMWR Series</i>	Martha F. Boyd, <i>Lead Visual Information Specialist</i>
Christine G. Casey, MD, <i>Deputy Editor, MMWR Series</i>	Maureen A. Leahy, Julia C. Martinroe,
Teresa F. Rutledge, <i>Managing Editor, MMWR Series</i>	Stephen R. Spriggs, Terraye M. Starr
David C. Johnson, <i>Lead Technical Writer-Editor</i>	<i>Visual Information Specialists</i>
Jeffrey D. Sokolow, MA, <i>Project Editor</i>	Quang M. Doan, MBA, Phyllis H. King
	<i>Information Technology Specialists</i>

### MMWR Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, <i>Chairman</i>	Timothy F. Jones, MD, Nashville, TN
Matthew L. Boulton, MD, MPH, Ann Arbor, MI	Rima F. Khabbaz, MD, Atlanta, GA
Virginia A. Caine, MD, Indianapolis, IN	Dennis G. Maki, MD, Madison, WI
Barbara A. Ellis, PhD, MS, Atlanta, GA	Patricia Quinlisk, MD, MPH, Des Moines, IA
Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA	Patrick L. Remington, MD, MPH, Madison, WI
David W. Fleming, MD, Seattle, WA	John V. Rullan, MD, MPH, San Juan, PR
William E. Halperin, MD, DrPH, MPH, Newark, NJ	William Schaffner, MD, Nashville, TN
King K. Holmes, MD, PhD, Seattle, WA	

# Prevention and Control of Meningococcal Disease

## Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Prepared by  
 Amanda C. Cohn, MD<sup>1</sup>  
 Jessica R. MacNeil, MPH<sup>1</sup>  
 Thomas A. Clark, MD<sup>1</sup>  
 Ismael R. Ortega-Sanchez, PhD<sup>2</sup>  
 Elizabeth Z. Briere, MD<sup>1</sup>  
 H. Cody Meissner, MD<sup>3</sup>  
 Carol J. Baker, MD<sup>4</sup>  
 Nancy E. Messonnier, MD<sup>1</sup>

<sup>1</sup>Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC

<sup>2</sup>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC

<sup>3</sup>Tufts University School of Medicine, Boston, Massachusetts

<sup>4</sup>Baylor College of Medicine, Houston, Texas

### Summary

*Meningococcal disease describes the spectrum of infections caused by Neisseria meningitidis, including meningitis, bacteremia, and bacteremic pneumonia. Two quadrivalent meningococcal polysaccharide-protein conjugate vaccines that provide protection against meningococcal serogroups A, C, W, and Y (MenACWY-D [Menactra, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania] and MenACWY-CRM [Menveo, manufactured by Novartis Vaccines, Cambridge, Massachusetts]) are licensed in the United States for use among persons aged 2 through 55 years. MenACWY-D also is licensed for use among infants and toddlers aged 9 through 23 months. Quadrivalent meningococcal polysaccharide vaccine (MPSV4 [Menomune, manufactured by sanofi pasteur, Inc., Swiftwater, Pennsylvania]) is the only vaccine licensed for use among persons aged ≥56 years. A bivalent meningococcal polysaccharide protein conjugate vaccine that provides protection against meningococcal serogroups C and Y along with Haemophilus influenzae type b (Hib) (Hib-MenCY-TT [MenHibrix, manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium]) is licensed for use in children aged 6 weeks through 18 months.*

*This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of meningococcal disease in the United States, specifically the changes in the recommendations published since 2005 (CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2005;54[No. RR-7]). As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations; it is intended for use by clinicians as a resource. ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination for persons at increased risk for meningococcal disease (i.e., persons who have persistent complement component deficiencies, persons who have anatomic or functional asplenia, microbiologists who routinely are exposed to isolates of N. meningitidis, military recruits, and persons who travel to or reside in areas in which meningococcal disease is hyperendemic or epidemic). Guidelines for antimicrobial chemoprophylaxis and for evaluation and management of suspected outbreaks of meningococcal disease also are provided.*

The material in this report originated in the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director, and the Division of Bacterial Diseases, Rana Hajjeh, MD, Director.  
**Corresponding preparer:** Amanda C. Cohn, MD, National Center for Immunizations and Respiratory Diseases, CDC. Telephone: 404-639-6039; E-mail: acohn@cdc.gov.

### Introduction

This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of meningococcal disease in the United States, specifically the changes in the recommendations published since 2005 (1), and describes the process undertaken and the rationale used in support of these recommendations.

This report is a comprehensive summary of previously published recommendations (Box 1) and does not contain any new recommendations; it is intended for use by clinicians as a resource. Guidelines for antimicrobial chemoprophylaxis (Appendix A) and evaluation and management of suspected outbreaks of meningococcal disease (Appendix B) also are provided.

Meningococcal disease describes the spectrum of infections caused by *Neisseria meningitidis*, including meningitis, bacteremia, and bacteremic pneumonia. Meningococcal disease develops rapidly, typically among previously healthy children and adolescents, and results in high morbidity and mortality. For unknown reasons, incidence has declined since the peak of disease in the late 1990s, and approximately 800–1,200 cases are reported annually in the United States. This decline began before implementation of routine use of meningococcal vaccines in adolescents and have occurred in all serogroups. Four vaccines are licensed in the United States and provide protection against four (A, C, W, and Y) and two (C and Y) serogroups (Table 1). Vaccines that protect against serogroup B meningococcal disease are not available in the United States.

Meningococcal vaccination is recommended for groups at increased risk for disease. These groups include adolescents, persons with certain medical conditions, and persons with increased risk for exposure. Among these risk groups, the number of vaccine doses (i.e., 2- or 4-dose primary series or a single dose with or without a booster dose) and vaccine product are determined by the indication for vaccination and age. In certain situations such as special dosing regimens (i.e., booster dose[s] or serial vaccination and 2-dose primary series for persons aged  $\geq 2$  years), off-label use of meningococcal vaccine has been recommended. Special dosing regimens have been recommended on the basis of data from studies of immunologic response to vaccination, postlicensure observational data, and the need for long-term protection in certain risk groups (2–4).

ACIP recommendations for meningococcal vaccination have been summarized (Box 2). Details regarding dosing (2- or 4-dose primary series or a single dose with or without a booster dose), contraindications, precautions, and special circumstances (e.g., adolescents infected with human immunodeficiency virus [HIV] and asplenic children) are described elsewhere in this report (see Recommendations for Use of Meningococcal Vaccines).

## Methods

ACIP's Meningococcal Vaccines Work Group\* (the Work Group) revised the meningococcal vaccine recommendations on the basis of the most current data on safety, efficacy, and immunogenicity of meningococcal vaccines. The Work Group

\*A list of the Work Group appears on Page 28.

### BOX 1. Timeline of meningococcal conjugate vaccine ACIP recommendations, 2005 — 2012

**2005:** Licensure of and first recommendation for routine vaccination of adolescents with MenACWY-D.\*

**2006:** Because of limited vaccine supply, vaccination was first limited to cohorts of children entering high school and entering college and persons aged 11–55 years at increased risk for meningococcal disease.†

**2007:** After vaccine supply became sufficient, ACIP recommended vaccination for all adolescents aged 11–18 years.§ ACIP recommended vaccination of children aged 2–10 years at increased risk for meningococcal disease.¶

**2009:** ACIP recommended booster dose for persons who remain at increased risk for meningococcal disease, administered every 5 years except for children who received their previous dose prior to their seventh birthday; these children should receive a booster dose 3 years after their previous dose.\*\*

**2010:** The Food and Drug Administration licensed a second vaccine product, MenACWY-CRM.†† ACIP added a booster dose at age 16 years and recommended a 2-dose primary series for all persons with asplenia, persistent complement component deficiency, and for persons with human immunodeficiency virus infection.§§

**2011:** ACIP recommended a 2-dose primary series for children aged 9–23 months at increased risk for meningococcal disease.¶¶

**2012:** ACIP recommended a 4-dose primary series of Hib-MenCY-TT for children aged 2–18 months at increased risk for meningococcal disease.\*\*\*

\* Source: CDC Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-7).

† Source: CDC. Notice to readers: limited supply of meningococcal conjugate vaccine, recommendation to defer vaccination of persons aged 11–12 years. MMWR 2006;55:567–8.

§ Source: CDC. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR 2007;56:794–5.

¶ Source: CDC. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2–10 years at increased risk for invasive meningococcal disease. MMWR 2007;56:1265–6.

\*\* Source: CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR 2009;58:1042–3.

†† Source: CDC. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59:273.

§§ Source: CDC. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60:72–6.

¶¶ Source: CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR 2011;60:1391–2.

\*\*\* Source: CDC. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR 2013;62:52–4.



TABLE 1. Licensed meningococcal vaccines — United States, 1981–2012

Formulation	Type	Trade name	Manufacturer	Licensed (yr)	Age group	Dose(s)	Serogroups
MPSV4*	Polysaccharide	Menomune	Sanofi Pasteur	1981	≥2 yrs	Single dose	A, C, W, and Y
MenACWY-D <sup>†</sup>	Conjugate	Menactra	Sanofi Pasteur	2005	11–55 yrs	Single dose	A, C, W, and Y
MenACWY-D <sup>†</sup>	Conjugate	Menactra	Sanofi Pasteur	2007	2–10 yrs	Single dose	A, C, W, and Y
MenACWY-D <sup>†</sup>	Conjugate	Menactra	Sanofi Pasteur	2011	9–23 mos	2-dose series	A, C, W, and Y
MenACWY-CRM <sup>§</sup>	Conjugate	Menveo	Novartis	2010	11–55 yrs	Single dose	A, C, W, and Y
MenACWY-CRM <sup>§</sup>	Conjugate	Menveo	Novartis	2011	2–10 yrs	Single dose	A, C, W, and Y
Hib-MenCY-TT <sup>¶</sup>	Conjugate	MenHibrix	GlaxoSmithKline	2012	6 wks–18 mos	4-dose series	C and Y

\* Package insert available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf>.

<sup>†</sup> Package insert available at <http://www.fda.gov/downloads/BiologicBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf>.

<sup>§</sup> Package insert available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf>.

<sup>¶</sup> Package insert available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdf>.

comprises a diverse group of health-care providers and public health officials, including professionals from academic medicine (pediatrics, family practice, internal medicine, and infectious disease specialists), federal and state public health professionals, and representatives of provider organizations. Since 2006, the Work Group has held teleconference meetings monthly and has held in-person meetings once or twice a year to discuss recently published studies, review current guidelines, and consider potential revisions to the recommendations. During these meetings, CDC staff members, pharmaceutical manufacturer representatives, and other academic partners delivered presentations on meningococcal disease epidemiology, immunogenicity and safety of meningococcal vaccines, cost effectiveness, programmatic considerations, and vaccine effectiveness studies.

The Work Group considers published, peer-reviewed studies as the primary source of data in making recommendations for the prevention and control of meningococcal disease. In addition, unpublished data (e.g., immunogenicity and safety data in age groups outside the licensed indication) that are relevant to issues under discussion also were considered. Randomized, controlled clinical trials for meningococcal vaccines are unable to evaluate clinical efficacy because of the low incidence of meningococcal disease; because efficacy cannot be measured, immunogenicity data are used as a surrogate for efficacy for licensure.

In addition, because rare adverse events might not be observed in prelicensure clinical trials because of the limited number of subjects enrolled, postlicensure observational data also were used in the assessment of meningococcal vaccines. Observational data included reports of vaccine failures, a postlicensure case-control study, Vaccine Adverse Events Reporting System (VAERS) data (12), and safety data collected from the Vaccine Safety Datalink (VSD) (13). Data reviewed on the incidence and burden of disease came from the Active Bacterial Core surveillance (ABCs) system and the National Notifiable Diseases Surveillance System (NNDSS) (14). The evidence for the benefits and risks of meningococcal vaccination in infants and toddlers was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework (GRADE

evidence tables for toddler and infant meningococcal vaccine are available at <http://www.cdc.gov/vaccines/acip/recs/GRADE/mening-vac-infants.html>).

Summaries of the data reviewed and Work Group discussions were presented to ACIP before changes were proposed to the recommendations. Proposed changes to meningococcal vaccine recommendations were presented at nine ACIP meetings from October 2007 through October 2012. During these nine meetings, recommendations were approved either as submitted or as amended and approved by ACIP, and ACIP members approved a draft of this report in April 2012. During the review process, CDC modified the statement to update and clarify wording in the report.

#### BOX 2. Meningococcal vaccination recommendations — Advisory Committee on Immunization Practices, 2013

ACIP recommends meningococcal vaccination for the following groups:

- Routine vaccination of adolescents aged 11 through 18 years (a single dose of vaccine should be administered at age 11 or 12 years, with a booster dose at age 16 years for persons who receive the first dose before age 16 years) (1,5–7).
- Routine vaccination of persons aged ≥2 months at increased risk for meningococcal disease, including (7–11):
  - Persons aged ≥2 months with certain medical conditions such as anatomical or functional asplenia or complement component deficiency (dosing schedule and interval for booster dose varies by age at time of previous vaccination).
  - Special populations such as unvaccinated or incompletely vaccinated first-year college students living in residence halls, military recruits, or microbiologists with occupational exposure (indication for booster dose 5 years after prior dose if at continued risk).
  - Persons aged ≥9 months who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic, particularly if contact with the local population will be prolonged.
- Vaccination of persons in at-risk groups (see Appendix B) to control outbreaks.


## Background

Meningococcal disease is a bacterial infection caused by *N. meningitidis*. Meningococcal disease usually presents clinically as one of three syndromes: meningitis (50.2%), bacteremia (37.5%), or bacteremic pneumonia (9.2%) (15). *N. meningitidis* colonizes mucosal surfaces of the nasopharynx and is transmitted through direct contact with large-droplet respiratory tract secretions from patients or asymptomatic carriers. Nasopharyngeal carriage rates are highest in adolescents and young adults (16,17), who serve as reservoirs for transmission of *N. meningitidis*. Invasive disease is an infrequent consequence of nasopharyngeal colonization.

## Epidemiology of Meningococcal Disease

During 2005–2011, an estimated 800–1,200 cases of meningococcal disease occurred annually in the United States, representing an incidence of 0.3 cases per 100,000 population (CDC, unpublished data, 2012). Incidence has declined annually since a peak of disease in the late 1990s (Figure 1). Even before routine use of a meningococcal conjugate vaccine in adolescents was recommended in 2005, the overall annual incidence of meningococcal disease had decreased 64%, from 1.1 cases per 100,000 population in 1996 to 0.4 cases per 100,000 population in 2005. Since 2005, declines have occurred among all age groups and in all vaccine-containing serogroups. In addition, incidence of disease attributable to serogroup B, a serogroup not included in the vaccine, declined

**FIGURE 1. Rate\* of meningococcal disease, by year — United States, 1970–2011†**



**Source:** CDC, Unpublished data, National Notifiable Diseases Surveillance System (NNDSS) for 1970–1996 and Active Bacterial Core surveillance (ABCs) system for 1997–2011.

\* Per 100,000 population.

† ABCs cases from 1997–2011 estimated to the U.S. population. In 2010, estimated case counts from ABCs were lower than cases reported to NNDSS and might not be representative.

for reasons that are not known. Although disease incidence is at historic lows, the overall case-fatality ratio remains at 10%–15%, and 11%–19% of survivors have long-term sequelae (e.g., neurologic disability, limb or digit loss, and hearing loss) (15,18,19).

Serogroups B, C, and Y are the major causes of meningococcal disease in the United States, each accounting for approximately one third of cases. However, the proportion of cases caused by each serogroup varies by age group. Approximately 60% of disease among children aged 0 through 59 months is caused by serogroup B *N. meningitidis*, which is not prevented by currently licensed vaccines (Table 1) (15). Serogroups C, Y, or W, which are included in vaccines available in the United States, cause 73% of all cases of meningococcal disease among persons aged  $\geq 11$  years (CDC, unpublished data, 2012).

In the United States, approximately 98% of cases of meningococcal disease are sporadic; however, outbreaks of meningococcal disease continue to occur (20). During 2010, two serogroup C meningococcal outbreaks were reported to CDC (CDC, unpublished data, 2010); in these two instances, meningococcal conjugate vaccination was recommended for a target age group in the community by local and state health officials as a control measure. These outbreaks ended shortly after vaccination campaigns were implemented, but whether vaccination prevented additional cases from occurring is unknown (21). In 2010, two serogroup B outbreaks also were reported to CDC. Cases associated with all reported outbreaks accounted for 108 (1.5%) of the 7,343 cases reported to CDC during 2005–2011 (CDC, unpublished data, 2012).

Incidence of meningococcal disease peaks among persons in three age groups: infants and children aged  $< 5$  years, adolescents and young adults aged 16 through 21 years, and adults aged  $\geq 65$  years (CDC, unpublished data; Table 2; Figure 2). The highest incidence in the first 5 years of life occurs among infants aged 0 through 5 months; 47% of serogroup C and Y disease among children aged 0 through 59 months occurs before age 6 months. Approximately 60% of disease in the first year of life is caused by serogroup B. Licensure in 2005 of the first MenACWY vaccine made it possible to address the second peak in disease incidence, which occurs in late adolescence. The third peak in incidence occurs among adults aged  $\geq 65$  years; approximately 60% of these cases are caused by serogroup Y, and 43% are characterized by bacteremic pneumonia. The highest case-fatality ratio (23.8%) is observed among adults aged  $\geq 65$  years (15).

## Postlicensure Impact of MenACWY

Since 2006, the National Immunization Survey–Teen (22) has assessed vaccination coverage annually among adolescents

**TABLE 2. Average annual estimated number and rate\* of cases of meningococcal disease, by age group and serogroup — United States, 2002–2011†**

Age group	Serogroup B		Serogroup C		Serogroup Y		Other§		Total	
	No.	(Rate)	No.	(Rate)	No.	(Rate)	No.	(Rate)	No.	(Rate)
< 1 yr	117	(2.8)	14	(0.3)	38	(0.9)	8	(0.2)	177	(4.3)
0–5 mos	74	(3.6)	5	(0.3)	23	(1.1)	6	(0.3)	108	(5.3)
6–11 mos	43	(2.1)	9	(0.4)	15	(0.7)	2	(0.1)	69	(3.4)
1 yr	28	(0.7)	9	(0.2)	2	(0.1)	3	(0.1)	42	(1.0)
2–4 yrs	38	(0.3)	16	(0.1)	8	(0.1)	7	(0.1)	69	(0.6)
5–10 yrs	31	(0.1)	16	(0.1)	12	(0)	3	(0)	62	(0.3)
11–18 yrs	28	(0.1)	43	(0.1)	43	(0.1)	10	(0)	124	(0.4)
19–21 yrs	26	(0.2)	23	(0.2)	16	(0.1)	3	(0)	68	(0.5)
22–24 yrs	21	(0.2)	22	(0.2)	7	(0.1)	1	(0)	51	(0.4)
25–64 yrs	93	(0.1)	129	(0.1)	125	(0.1)	21	(0)	368	(0.2)
≥65 yrs	20	(0.1)	33	(0.1)	114	(0.3)	19	(0.1)	186	(0.5)
<b>Total</b>	<b>402</b>	<b>(0.1)</b>	<b>305</b>	<b>(0.1)</b>	<b>365</b>	<b>(0.1)</b>	<b>76</b>	<b>(0)</b>	<b>1,146</b>	<b>(0.4)</b>

Source: CDC, Unpublished data, Active Bacterial Core surveillance (ABCs) system, 2002–2011.

\* Per 100,000 population.

† ABCs cases from 2002–2011 estimated to the U.S. population with 18% correction for underreporting. In 2010, estimated case counts from ABCs were lower than cases reported to the National Notifiable Diseases Surveillance System and might not be representative.

§ Includes serogroup W135, nongroupable, and other serogroups.

aged 13 through 17 years. Among this age group, coverage with MenACWY has increased from 10.2% in 2006 to 70.5% in 2011 (22,23); coverage by state in 2011 ranged from 27.6% to 92.1% (23). One method for assessing the impact of MenACWY is to monitor changes in disease incidence caused by vaccine serogroups. During 2005–2009, MenACWY-D was the only meningococcal conjugate vaccine licensed in the United States. Therefore, postlicensure data primarily reflect use of MenACWY-D. During 2009 and 2010, when routine vaccine use was recommended and supply was sufficient, incidence of serogroup C and Y meningococcal disease declined among adolescents aged 11 through 18 years. Incidence did not decline in other age groups, suggesting an impact of vaccination on adolescent disease, but no evidence of herd protection (Table 3).

During 2006–2010 (i.e., in the first 5 years after routine use of meningococcal vaccine was recommended), CDC received reports of approximately 30 cases of serogroups C and Y meningococcal disease among persons who had received the vaccine. The case-fatality ratio was similar among persons who had received vaccine compared with those who were unvaccinated (CDC, unpublished data, 2012). To assess vaccine effectiveness among adolescents, CDC carried out a simulation study of breakthrough disease (i.e., cases that occur among vaccine recipients) and a case-control study (24,25). The first estimate of vaccine effectiveness was based on a simulation approach that calculated the expected number of cases in vaccinated persons. The expected number of breakthrough cases was calculated from available vaccine coverage and disease incidence data, and estimates of expected vaccine effectiveness were based on prelicensure serologic evidence of immune response. When the number of expected


cases was compared with the observed number of breakthrough cases, vaccine effectiveness during 2005–2008 was estimated to be 80%–85% (24). Of the 13 reports of breakthrough disease for which data on underlying conditions were available, four persons had underlying conditions or behaviors associated with an increased risk for bacterial infections, including 1) Type 1 diabetes mellitus; 2) current smoking; 3) history of bacterial meningitis and recurrent infections; and 4) aplastic anemia, paroxysmal nocturnal hemoglobinuria, and receipt of eculizumab (which blocks complement protein C5) (24).

A case-control study evaluating the vaccine effectiveness of meningococcal conjugate vaccine in adolescents began in January 2006 (25). Because MenACWY-D was the only licensed conjugate vaccine until February 2010, the preliminary results provided in this report are estimates for MenACWY-D only. As of August 29, 2012, a total of 157 case-patients and 180 controls were enrolled in the effectiveness study. The overall estimate of vaccine effectiveness in adolescents vaccinated 0 through 6 years earlier was 69% (95% confidence interval [CI] = 50%–81%). Vaccine effectiveness was 82% (CI = 54%–93%) for adolescents vaccinated <1 year earlier, 80% (CI = 52%–92%) for adolescents vaccinated 1–<2 years earlier, 71% (CI = 34%–87%) for adolescents vaccinated 2–<3 years earlier, and 59% (CI = 5%–83%) for adolescents vaccinated 3–<6 years earlier (25). Although CIs around the point estimates are wide, these results suggest that vaccine effectiveness wanes over time.

## Risk Factors for Meningococcal Disease

Risk factors for meningococcal disease can be grouped into organism, host, and environmental factors. Noncapsular strains of *N. meningitidis* are less virulent than capsular strains. More

**FIGURE 2. Rate\* of meningococcal disease, by age group — United States, 2002–2011†**



Source: Unpublished data, Active Bacterial Core surveillance (ABCs) system.  
\* Per 100,000 population.

† ABCs cases from 2002–2011 estimated to the U.S. population with 18% correction for nonculture-confirmed cases. In 2010, estimated case counts from ABCs were lower than cases reported to the National Notifiable Diseases Surveillance System and might not be representative.

virulent strains of *N. meningitidis* can circulate in a population and cause increased incidence of disease or increased mortality (26). Persons who have persistent (i.e., genetic) deficiencies in the common complement pathway (e.g., C3, properdin, Factor D, Factor H, or C5–C9) have up to a 10,000-fold increased risk for meningococcal disease and can experience recurrent disease (27,28). Although persons with anatomic or functional asplenia also appear to be at increased risk for meningococcal disease, the data are less compelling than data that demonstrate the increased risk for pneumococcal disease in patients with asplenia (29).

Antecedent viral infection, household crowding, chronic underlying illness, and both active and passive smoking are associated with increased risk for meningococcal disease (30–36). Early U.S. studies of risk factors for meningococcal disease

demonstrated that blacks and persons of low socioeconomic status were at higher risk for meningococcal disease than other persons (37,38); however, race and low socioeconomic status also are considered markers for other risk factors (e.g., smoking and household crowding) (31). As disease incidence has decreased, differences by race also have decreased, and no difference in disease incidence exists now between blacks and whites (15).

One study of meningococcal disease among clinical microbiologists who work routinely with *N. meningitidis* isolates demonstrated an attack rate of 13 cases per 100,000 microbiologists and increased case-fatality ratios. Of the 16 cases identified, 15 occurred in clinical microbiologists who were not using respiratory protection at the time of exposure (39,40). Health-care personnel in general are not identified as a high-risk group unless a person is exposed to respiratory secretions of someone with meningococcal disease.

Because the incidence of both meningococcal disease and HIV infection are low in the United States, studies have not established HIV as an independent risk factor for meningococcal infection (32,41). A recent study in the ABCs sites demonstrated that the cumulative average incidence of meningococcal disease among patients aged 25 through 64 years who meet CDC’s surveillance case definition for acquired immune deficiency syndrome (AIDS) was 3.5 cases per 100,000 person years (CI = 2.0–5.6), compared with an incidence of 0.3 cases per 100,000 person years (CI = 0.2–0.3) for persons of the same age group in the general population (rate ratio: 12.6; CI = 7.9–20.2) (42). These incidence rates were not adjusted for potential confounding risk factors such as smoking; however, the incidence of meningococcal disease is higher in persons with AIDS compared with the general adult population.

## Meningococcal Disease Among College Students

Studies conducted in the 1990s that focused on quantifying the risk for meningococcal disease among college students demonstrated

**TABLE 3. Rate\* of meningococcal disease, by age group and serogroup — United States, 1998–2011†**

Years	Serogroup C, Y, W						Serogroup B					
	<1 yr		11–19 yrs		≥20 yrs		<1 yr		11–19 yrs		≥20 yrs	
	Rate	(CI)	Rate	(CI)	Rate	(CI)	Rate	(CI)	Rate	(CI)	Rate	(CI)
1998–1999	5.86	(4.24–7.90)	1.13	(0.90–1.41)	0.47	(0.41–0.54)	3.32	(2.21–4.86)	0.22	(0.13–0.36)	0.14	(0.11–0.19)
2000–2001	2.32	(1.45–3.55)	0.71	(0.54–0.91)	0.38	(0.33–0.44)	4.30	(3.02–5.95)	0.27	(0.17–0.41)	0.13	(0.10–0.17)
2002–2003	2.06	(1.23–3.26)	0.55	(0.40–0.73)	0.25	(0.21–0.30)	4.30	(3.06–5.90)	0.20	(0.12–0.32)	0.11	(0.09–0.15)
2004–2005	0.77	(0.33–1.55)	0.27	(0.17–0.39)	0.17	(0.14–0.21)	3.10	(2.10–4.42)	0.11	(0.06–0.20)	0.07	(0.05–0.09)
2006–2007	1.20	(0.61–2.11)	0.31	(0.21–0.45)	0.23	(0.19–0.28)	2.11	(1.32–3.22)	0.05	(0.02–0.12)	0.06	(0.04–0.09)
2008–2009	0.93	(0.48–1.69)	0.15	(0.08–0.26)	0.23	(0.19–0.27)	2.92	(1.99–4.18)	0.10	(0.04–0.18)	0.07	(0.05–0.10)
2010–2011	1.37	(0.74–2.33)	0.05	(0.02–0.12)	0.14	(0.11–0.18)	1.33	(0.72–2.29)	0.00	(0.00–0.05)	0.03	(0.02–0.05)

Abbreviation: CI = 95% confidence interval.

Source: CDC, Unpublished data, Active Bacterial Core surveillance (ABCs) system, 1998–2011.

\* Per 100,000 population.

† ABCs cases from 1998–2011 estimated to the U.S. population with 18% correction for nonculture-confirmed cases. In 2010, estimated case counts from ABCs were lower than cases reported to the National Notifiable Diseases Surveillance System and might not be representative.



that the overall incidence among college students was similar to or somewhat lower than that observed among persons of approximately the same age in the general population (43). However, in a case-control study involving 50 cases among college students (44), multivariate analysis indicated that first-year college students living in residence halls were at higher risk for meningococcal disease than other students (matched odds ratio [OR]: 3.6; CI = 1.6–8.5). Other studies in the 1990s yielded similar results (45,46).

In 2000, before licensure of meningococcal conjugate vaccines, ACIP recommended that first-year college students living in residence halls consider vaccination with the quadrivalent meningococcal polysaccharide vaccine (MPSV4), which was licensed in 1981 (47). Since the 2000 ACIP recommendation, many colleges have required all matriculating students to be vaccinated. Thirty-six states and the District of Columbia have mandates requiring education of college students about meningococcal vaccines or proof of meningococcal vaccination for attendance (a list of these states is available at <http://www.immunize.org/laws/menin.asp>). When the first meningococcal conjugate vaccine was licensed in 2005, ACIP recommended that all first-year college students living in residence halls be vaccinated with MenACWY-D (1).

## Meningococcal Vaccines

Four meningococcal vaccines that contain purified capsular polysaccharide(s) alone or that are conjugated to a carrier protein are licensed and available in the United States for the prevention of invasive disease caused by *N. meningitidis* serogroups A, C, W and Y (Table 1). As stated in the package inserts (Table 1), for the quadrivalent meningococcal polysaccharide vaccine (MPSV4), effectiveness of the vaccine (A and C components) was supported by clinical efficacy data from studies with meningococcal monovalent A and C and bivalent A/C polysaccharide vaccines, and inferred by use of serum bactericidal antibody assay (SBA) (Y and W components) as an indicator of protection against serogroup-specific meningococcal disease. Effectiveness of the three meningococcal conjugate vaccines, which were licensed after MPSV4, was inferred by comparing SBA measurements of the new vaccine with corresponding antibody responses of the U.S.-licensed meningococcal vaccine representing the standard of care at the time (among persons aged 2 through 55 years) or by achieving a seroresponse at or above a predefined bactericidal antibody titer (among children aged 2 through 23 months).

### Immunologic Surrogate of Protection

Protection against invasive meningococcal disease is mediated by serum bactericidal antibodies to meningococcal

capsular polysaccharides or to protein antigens. Studies have demonstrated that almost all persons who developed invasive serogroup C meningococcal disease had sera that lacked bactericidal activity to the pathogenic meningococcal strain (48,49). In contrast, persons with detectable SBA against a specific strain rarely developed disease.

Complement-dependent bactericidal activity can be measured reliably by use of a serum bactericidal antibody assay with a human (hSBA) or baby rabbit (rSBA) complement source. A defined bactericidal antibody titer that is indicative of protection against invasive meningococcal disease is assay-dependent. When sera are tested using a human complement source, SBA titers  $\geq 1:4$  are considered protective. Because of greater susceptibility of meningococci to lysis by rabbit complement, antibody titers measured by an rSBA assay are elevated compared with titers generated by an hSBA assay (50–52). Population-based surveillance data from the United Kingdom indicate that following mass vaccination with meningococcal serogroup C conjugate vaccine, bactericidal titers between 1:8 and 1:64, measured by rSBA, can be protective (53). Antibody titers measured by rSBA and hSBA assays are not directly comparable.

## Meningococcal Quadrivalent Polysaccharide Vaccine (MPSV4)

MPSV4, a quadrivalent (serogroups A, C, Y, and W) meningococcal polysaccharide vaccine (Menomune, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania), was licensed in 1981. MPSV4 is approved by FDA for use as a single dose in persons aged  $\geq 2$  years. Each dose consists of 50  $\mu\text{g}$  of each of the four purified capsular polysaccharides from serogroups A, C, W, and Y. MPSV4 is available in single-dose (0.5-mL) and 10-dose (5-mL) vials and is administered as a subcutaneous injection. Further information is provided in the package insert (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131653.pdf>).

## Quadrivalent Meningococcal Conjugate Vaccines (MenACWY)

Conjugation (i.e., covalent coupling) of a meningococcal capsular polysaccharide to a protein carrier that contains T-lymphocyte epitopes changes the nature of the human immune response to the polysaccharide from T-lymphocyte-independent to T-lymphocyte-dependent. Conjugation results in an improved primary response to the polysaccharide antigen, especially in infants, and a stronger anamnestic response (i.e., immunologic memory) at reexposure (54). As of July 2012,

two quadrivalent (serogroups A, C, Y, and W) and one bivalent (serogroups C and Y) meningococcal polysaccharide-protein conjugate vaccines have been licensed by FDA: MenACWY-D (Menactra, manufactured by sanofi pasteur, Inc., Swiftwater, Pennsylvania), MenACWY-CRM (Menveo, manufactured by Novartis Vaccines, Cambridge, Massachusetts), and Hib-MenCY-TT (MenHibrix, manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium).

### MenACWY-D

MenACWY-D was licensed by FDA in January 2005. MenACWY-D is approved by FDA as a single dose for persons aged 2 through 55 years and as a 2-dose series in children aged 9 through 23 months. A single 0.5-mL dose of MenACWY-D contains 4  $\mu$ g each of capsular polysaccharide from serogroups A, C, Y, and W conjugated to approximately 48  $\mu$ g of diphtheria toxoid. MenACWY-D is available in single-dose vials and is administered as an intramuscular injection. More information is provided in the package insert (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf>).

MenACWY-D often will be administered concomitantly with other vaccines (e.g., with typhoid vaccines in international travelers or with other routinely recommended vaccinations in adolescents and young children). As stated in the package insert (Table 1), concomitant administration of MenACWY-D and typhoid vaccines (Typhoid Vi Polysaccharide Vaccine, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was evaluated in persons aged 18 through 55 years, and concomitant administration of MenACWY-D and Td (Tetanus and Diphtheria Toxoids Adsorbed, For Adult Use; manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) vaccine was evaluated in persons aged 11 through 17 years. Concomitant administration of typhoid vaccine and MenACWY-D did not affect the immunogenicity of either vaccine. The proportion of participants with a fourfold or greater increase in rSBA titer to meningococcal serogroups C, Y, and W was higher when MenACWY-D was administered with Td (86%–96%) than when MenACWY-D was administered 1 month following administration of Td (65%–91%). Antitetanus and antidiphtheria antibody responses were similar in both study groups.

Affect on immunogenicity varied by vaccine administered concomitantly. Concomitant administration of MMRV (measles, mumps, rubella, and varicella combination vaccine) and the fourth dose of PCV7 (7-valent pneumococcal conjugate vaccine) and a second MenACWY-D dose was evaluated in children aged 12 months who had received the first MenACWY-D dose at age 9 months. Lower geometric mean concentrations (GMCs) of IgG antibodies to some pneumococcal serotypes were observed compared with corresponding IgG GMCs when PCV7

was administered alone. The noninferiority criteria (twofold differences in IgG GMC) for the prespecified pneumococcal endpoints were not met for PCV7 serotypes 4, 6B, and 18C (10). However, the IgG antibody responses and opsonophagocytic responses to the seven pneumococcal vaccine serotypes were still robust. No interference with immune responses to antigens contained in MMRV was observed. Details about these studies are provided in the package insert.

### MenACWY-CRM

MenACWY-CRM was licensed by FDA in February 2010. MenACWY-CRM is approved by FDA as a single dose for persons aged 2 through 55 years. A single 0.5-mL dose of vaccine contains 10  $\mu$ g of capsular polysaccharide from serogroup A and 5  $\mu$ g of capsular polysaccharide from serogroups C, Y, and W conjugated to approximately 33–64  $\mu$ g of CRM<sub>197</sub>, a naturally occurring, nontoxic form of diphtheria toxin from *Corynebacterium diphtheriae*. MenACWY-CRM must be prepared by reconstituting the lyophilized serogroup A conjugate with the liquid serogroups C, W, and Y conjugate components. More information is provided in the package insert (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf>).

MenACWY-CRM is likely to be administered concomitantly with tetanus and diphtheria toxoids and acellular pertussis vaccine absorbed (Tdap) because both vaccines are routinely recommended for adolescents. Concomitant use of MenACWY-CRM and Tdap was evaluated in an open-label, randomized, controlled study conducted among adolescents aged 11 through 18 years. Antibody responses to pertussis antigens were lower when MenACWY-CRM and Tdap were administered concomitantly than when MenACWY-CRM was administered 1 month following Tdap: antipertussis toxin GMCs were 51 versus 63 EIA Units (EU)/mL, antifilamentous hemagglutinin GMCs were 342 versus 511 EU/mL, and antipertactin GMCs were 819 versus 1,197 EU/mL, respectively. Because no serologic correlates of protection for pertussis have been established, the clinical implications of the lower pertussis antigen responses are unknown. Immune responses to MenACWY-CRM and to diphtheria and tetanus toxoid antigens in Tdap were similar. Details about this study are provided in the package insert (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf>).

### Hib-MenCY-TT

Hib-MenCY-TT was licensed by FDA in June 2012. Hib-MenCY-TT is approved by FDA as a 4-dose series for children

aged 6 weeks through 18 months. Hib-MenCY-TT is supplied as a sterile, lyophilized powder that is reconstituted at the time of use with the accompanying saline diluent for intramuscular injection. A single 0.5mL dose of vaccine contains 5 µg of capsular polysaccharide from serogroups C conjugated to approximately 5 µg of tetanus toxoid, 5 µg of capsular polysaccharide from serogroup Y conjugated to approximately 6.5 µg of tetanus toxoid, and 2.5 µg of *Haemophilus influenzae* type b capsular polysaccharide conjugated to approximately 6.25 µg of tetanus toxoid. More information is provided in the package insert (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdf>).

Concomitant administration with routinely recommended vaccines is anticipated. Hib-MenCY-TT was co-administered with DTaP-HepB-IPV and 7-valent pneumococcal conjugate vaccine (PCV7) at ages 2, 4, and 6 months, and with measles-mumps-rubella, varicella, and PCV7 vaccines at age 12–15 months. In clinical trials, no decreased immunogenicity of coadministered vaccines was observed (55,56). A randomized, controlled, multicenter study evaluated the percentage of subjects with hSBA titers ≥1:8 at 2 months after the second dose was administered at age 4 months. In the group vaccinated with Hib-MenCY-TT, 94% and 83% of subjects achieved hSBA antibody titers ≥1:8 for meningococcal serogroups C and Y, respectively, after dose 2 (57). Rates of local and systemic adverse events observed after administration of Hib-MenCY-TT were comparable to rates observed after administration of Hib-TT. Thus, Hib-MenCY-TT was found to be safe and immunogenic for both Hib and meningococcal serogroups C and Y.

### Experience with Meningococcal Polysaccharide Vaccine (MPSV4)

The immunogenicity and clinical efficacy of serogroups A and C meningococcal polysaccharide vaccines are well-established. The serogroup A polysaccharide induces antibody response among children as young as age 3 months, although a response comparable with that occurring in adults is not achieved until age 4 to 5 years; the serogroup C component is poorly immunogenic among recipients aged <24 months (58–60). The serogroups A and C vaccines have demonstrated estimated clinical efficacies of ≥85% among school-aged children and adults during outbreaks (61–64). Although clinical protection has not been documented, vaccination with Y and W polysaccharides induces production of bactericidal antibodies (65–67). The antibody responses to each of the four polysaccharides in the quadrivalent vaccine are serogroup specific and independent (i.e., there is no cross-protection).

Reduced clinical efficacy has not been demonstrated among persons who have received multiple doses of polysaccharide vaccine. However, serologic studies have indicated that multiple

doses of serogroup A and C polysaccharide vaccine can cause immunologic hyporesponsiveness (i.e., a reduced antibody response after subsequent doses with the same polysaccharide antigen) to group A (68,69) and C polysaccharide (70,71). Hyporesponsiveness to serogroups C and A polysaccharides can be overcome partially by vaccination with serogroup C or A conjugate vaccine (72).

### Experience with Meningococcal Conjugate Vaccines

An advantage of vaccines in which proteins are conjugated to polysaccharide antigens is their ability to elicit immunologic memory. Meningococcal conjugate vaccines prime the immune system, and immunologic memory persists even in the absence of detectable bactericidal antibodies. However, while vaccine-induced immunologic memory might be protective against infection with other disease-causing encapsulated bacteria, the presence of detectable circulating antibody appears to be important for protection against *N. meningitidis*. In most cases, meningococcal infection progresses rapidly, with fulminant disease occurring within 1–4 days after invasion of normally sterile body sites.

Studies of antibody response kinetics following boosting with serogroup C meningococcal vaccines in the United Kingdom have demonstrated that up to 10 days might be required to achieve protective rSBA titers ≥1:8 in healthy young adults (73). If antibody is not present in sufficient quantity before colonization, this delay in antibody synthesis might not be rapid enough to protect against infection with *N. meningitidis*. Analyses of breakthrough disease among previously vaccinated persons in the United Kingdom identified evidence of immunologic priming but low SBA activity at the time of disease onset. Although infected persons demonstrated a boost response to *N. meningitidis* and bactericidal antibody levels increased, the response was not rapid enough to prevent disease (74). Therefore, circulating bactericidal antibody at the time of exposure appears to be critical for protection against meningococcal disease.

Meningococcal vaccination coverage has increased in the United States, but no evidence of herd protection has been demonstrated (75). However, herd protection has been an important component associated with long-term protection with use of serogroup C meningococcal vaccine in the United Kingdom and other countries. Evidence of herd protection after the MenC vaccine program was implemented in the United Kingdom, where catch-up campaigns led rapidly to high coverage in all persons aged 2 months through 22 years, included reduction in nasopharyngeal carriage of serogroup C *N. meningitidis* and reduction of serogroup C disease in unvaccinated age groups (infants too young to be vaccinated and



adults aged  $\geq 25$  years) (76,77). One year after introduction of MenC vaccine in the United Kingdom, serogroup C carriage was reduced 66% among students aged 15 through 17 years (78). Attack rates among unvaccinated children aged  $< 1$  year in the United Kingdom also declined 67% in the 4 years following vaccine introduction.

During 1998–2009, the incidence of serogroup C disease in the United Kingdom in persons aged  $> 25$  years decreased from 0.55 per 100,000 persons to 0.02 per 100,000 persons, and the total number of cases in infants aged  $< 3$  months decreased from 13 in 1998 to one in 2009 (79). The vaccination program in the United Kingdom effectively eliminated a single highly virulent clone that had high expression of the polysaccharide capsule (80). Variability of strains, different vaccines, and different target populations likely account for the differences in vaccine impact observed to date in the United States compared with the United Kingdom.

### Persistence of Antibodies After Vaccination with MenACWY

Longitudinal vaccine effectiveness studies as well as evaluation of persistence of antibody after vaccination with MenACWY vaccines are critical to monitoring duration of protection. Persistence of detectable bactericidal antibodies 3 years after a single vaccination (administered at age 11 through 18 years) and antibody responses consistent with immunologic boosting have been observed in adolescent MenACWY-D recipients. Lower bactericidal antibody titers to each of the four serogroups were observed 3 to 5 years postvaccination relative to bactericidal antibody responses observed 1 month after a single MenACWY dose (81,82). For serogroup C, geometric mean antibody titers (GMTs) declined by as much as 90% over 3 years. The proportion of adolescents vaccinated at age 11 years with MenACWY-D determined to have protective antibodies 3 years later was 71%–95% (81). Antibody persistence following MenACWY-CRM vaccination also has been described. Among persons vaccinated with a single dose of MenACWY-CRM at age 11 through 18 years, approximately 65% maintained hSBA  $\geq 1:8$  for serogroups C and Y at 21 months and 36 months postvaccination (83,84). These serologic data have been summarized (Table 4); the data are consistent with results of studies discussed previously in this report that suggest waning vaccine effectiveness.

Other serologic studies conducted among infants and young children demonstrate a similar decline in hSBA titers. The proportion of children aged 2 years with hSBA titers  $\geq 1:4$  6 months following a single vaccination with MenACWY-D was approximately 50% for serogroups C, Y, and W-135 (85,86). In another study, approximately 60 infants were vaccinated at age 9 months and at age 12 or 15 months, and hSBA titers were measured approximately 3 years after the second dose. Fewer than half of the study subjects had maintained

an hSBA titer  $\geq 1:8$  for any of the meningococcal serogroups (ACIP, unpublished data, 2011). Among infants who received a 4-dose series of Hib-MenCY-TT, 83% and 70% of subjects had persistence of bactericidal antibody for serogroups C and Y, respectively, 5 years after the fourth dose (87).

### Immunogenicity and Safety of a Booster Dose of MenACWY

In three separate studies, bactericidal antibody responses after a booster dose of MenACWY-D were evaluated in adolescents 3 years after receiving a MenACWY-D primary dose (administered at age 11 through 18 years), in children 5 years after receiving a MenACWY-D primary dose (administered at age 2 through 10 years) and after a booster dose of MenACWY-CRM in adolescents 3 years after a MenACWY-CRM primary dose (administered at age 11 through 18 years) (ACIP, unpublished data, 2009). At both 3 and 5 years after the first MenACWY conjugate vaccine dose, revaccination with the same MenACWY conjugate vaccine elicited substantially higher GMTs compared with the titers elicited after a single primary dose. In the MenACWY-D booster studies, when rSBA was used as a measure of immune response, a dose administered 5 years after the first dose (administered at age 2 through 10 years) elicited a GMT for serogroup C of 23,613 compared with 9,045 among meningococcal vaccine-naïve subjects aged 7 through 15 years who had received a single primary dose (ACIP, unpublished data, 2010).

In all of the studies, local and systemic reactions following a booster dose of either MenACWY conjugate vaccine were comparable with reactions in persons receiving a primary dose of the same vaccine. The duration of protection after a booster dose in adolescents, when administered at ages 16 through 18 years, is not known, but expert members of the Work Group expect protection to last through at least age 21 years. A booster dose of MenACWY-D in children initially vaccinated with MenACWY-D at age 9 months and then at age 12 or 15 months was evaluated 3 years after the second administered dose. Following booster immunization, at least 98% of children achieved an hSBA titer  $\geq 1:8$  to each of the serogroups. ACIP evaluated the data available and decided to recommend a booster dose of MenACWY for persons who remained at increased risk for meningococcal disease and for adolescents at age 16 years.

### Interchangeability of Vaccine Product for the Booster Dose

Limited data suggest that different conjugate vaccine products can be used interchangeably. The safety and immunogenicity of MenACWY-CRM vaccination have been evaluated in adolescents 3 years after they received a single dose of MenACWY-CRM or MenACWY-D administered at



**TABLE 4. Summary of serogroup C bactericidal antibody persistence as determined by serum bactericidal antibody assay (SBA) 2–5 years after vaccination with meningococcal vaccines — United States, 2006–2010**

Age group at vaccination (yrs)	Yrs post-vaccination	Serogroup C SBA	Vaccine	Vaccine recipients	
				No.	% with protective antibody levels
11–18*	2	% hSBA ≥1:8	Menveo	273	62
			Menactra	185	58
11–18†	3	% rSBA ≥1:128	Menactra	71	75
			MPSV4	72	60
2–10‡	5	% rSBA ≥1:128	Menactra	161	55
			MPSV4	207	42
11–18†	5	% rSBA ≥1:128	Menactra	50	56
			MPSV4	68	62
11–17§	5	% hSBA ≥1:8	Menveo	50	72
			MPSV4	50	62

**Abbreviations:** hSBA = SBA using human complement; rSBA = SBA using baby rabbit complement; MPSV4 = quadrivalent meningococcal polysaccharide vaccine.

\* Source: Gill C, Baxter R, Anemona A, Ciavarró G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. *Human Vaccines* 2010;6:881–7.

† Source: Advisory Committee on Immunization Practices, unpublished data, 2009.

§ Source: Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrliin T, Dull T. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. *Pediatr Infect Dis J* [Epub ahead of print]. DOI: 10.1097/INF.0b013e318279ac38.

age 11 through 18 years (88). Following revaccination with MenACWY-CRM, ≥99% of persons previously immunized with MenACWY-CRM or MenACWY-D had hSBA titers ≥1:8. The solicited adverse event rates (including injection-site reactions) reported after revaccination were similar to the rates reported after primary immunization (88). No data exist on the use of MenACWY-D following primary vaccination with MenACWY-CRM.

### Immune Response of Meningococcal Conjugate Vaccines in Special Populations

Asplenic persons are at increased risk for invasive infection caused by many encapsulated bacteria, including *N. meningitidis*. Moreover, the mortality rate is 40%–70% among these persons when they become infected with *N. meningitidis*. Asplenic persons achieve significantly lower geometric mean rSBA titers than healthy persons after vaccination with a meningococcal C conjugate vaccine, with 20% not achieving rSBA titers ≥1:8. This proportion was reduced to 7% when a second dose of vaccine was administered to nonresponders 2 months later (2), suggesting that a 2-dose primary series might be effective in achieving higher circulating antibody levels and persistence of bactericidal antibodies. The complement pathway is important in prevention of meningococcal disease, and *N. meningitidis* is the primary bacterial pathogen affecting persons with inherited late component complement or properdin deficiency. Although persons with late-component

complement deficiency are able to mount an overall antibody response equal to or greater than complement-sufficient persons after vaccination with MPSV4, antibody titers wane more rapidly in persons with complement component deficiency, and higher antibody levels are needed for other clearance mechanisms, such as opsonization to function (27,28).

Although persons with HIV infection are not at as high a risk for meningococcal disease as persons with persistent complement component deficiency or asplenia, reduced antibody responses following meningococcal vaccination have been reported in persons with HIV infection (3,4). Two studies have investigated the response rates to MenACWY-D among HIV-infected adolescents and children (3,4). Among HIV-infected adolescents and young adults vaccinated with a single dose at age 11 through

24 years, response rates to vaccination measured by rSBA titers ≥1:128 were 86%, 55%, 73%, and 72% for serogroups A, C, Y, and W, respectively. Response rates were significantly lower among patients with a CD4+ T-lymphocyte percentage of <15% (p = 0.003) or viral loads >10,000 copies/mL (p = 0.005) (4).

### Postlicensure Safety Surveillance for Meningococcal Conjugate Vaccines

Surveillance for adverse events following receipt of meningococcal conjugate vaccines has been performed primarily by two systems in the United States, VAERS and VSD. VAERS is a national passive surveillance system operated jointly by CDC and FDA that receives reports of adverse events following vaccination from health-care personnel, manufacturers, vaccine recipients, and others. The VAERS reporting form collects information about vaccine recipient demographics, vaccines administered, recipient medical history, and signs and symptoms of adverse events. VAERS can generate, but not test, vaccine safety hypotheses and is subject to several limitations, including reporting biases and inconsistent data quality (12.) Passive surveillance data from VAERS should be interpreted with caution. The VSD project is a collaborative effort between CDC and 10 managed care organizations. The VSD project allows for planned vaccination safety studies as well as timely investigations of hypotheses that arise from review of medical literature, reports to VAERS, changes in immunization schedules, or introduction of new vaccines (13).

## Adverse Events after Receipt of Meningococcal Conjugate Vaccine

### MenACWY-D

From licensure of MenACWY-D in January 14, 2005, through September 30, 2011, VAERS received 8,592 reports involving receipt of MenACWY-D in the United States; 89.0% reports involved persons aged 11 through 19 years. MenACWY-D was administered alone in 22.5% of case reports. The median time from vaccination to onset of an adverse event was 1 day. Males accounted for 40.6% of the reported events. The most frequently reported adverse events were fever 16.8%, headache 16.0%, injection site erythema 14.6%, and dizziness 13.4%. Syncope previously has been identified as an adverse event following any vaccination, with a higher proportion of syncope events reported to VAERS having occurred in adolescents compared with other age groups (89). Syncope was reported in 10.0% of reports involving MenACWY-D. Among all MenACWY-D reports, 563 (6.6%) were coded as serious (i.e., resulted in death, life-threatening illness, hospitalization, prolongation of hospitalization, or permanent disability).

Among those reports coded as serious, the most frequent adverse events reported included headache (37.5%), fever (32.5%), vomiting (23.6%), and nausea (22.2%). Cases of Guillain-Barré Syndrome (GBS) were recorded in 86 (15.3%) reports coded as serious, although the diagnosis has not been validated by medical records for all reports. A total of 24 (0.3%) deaths were reported, each of which was documented by autopsy report or other medical records and occurred in persons aged 10 through 23 years.

Among the 24 reports of death, 11 (45.8%) indicated that the cause of death was meningococcal infection (nine with a serogroup included in the vaccine and two with a nonvaccine serogroup). Among the other 13 (54.2%) reports of death, which occurred from the day of vaccination to 127 days following vaccination, stated causes of death were cardiac (five), neurologic (two), infectious (two), behavioral (i.e., suicide) (two), rheumatologic (one), and unexplained (one). There was no pattern among these reports. Except for the finding of GBS, which was further evaluated and is discussed below, no signals were identified in VAERS after MenACWY-D vaccination.

### MenACWY-CRM

During February 19, 2010–September 30, 2011, VAERS received 284 reports of adverse events following receipt of MenACWY-CRM in the United States. Approximately three fourths (78.9%) of the reported events concerned persons aged 11 through 19 years. Males were the subject of 44.0% of reports; 45.4% of reports involved other vaccines administered at the same time, and 4.2% of reports were coded as serious. One death was reported, with the cause of death stated as unexplained. The

median time from vaccination to adverse event onset was 0 days (the day of vaccination). The most common adverse event reported was injection-site erythema (19.7%) followed by injection-site swelling (13.7%). Syncope was reported in 8.8% of reports. No cases of GBS were reported. Administration errors (e.g., wrong diluent used or subcutaneous injection) without adverse events were described in 15.5% of reports involving MenACWY-CRM.

## Guillain-Barré Syndrome and Meningococcal Conjugate Vaccine

In 2005, shortly after licensure of MenACWY-D, several cases of Guillain-Barré Syndrome (GBS) were reported to VAERS (90,91). Symptom onset clustered approximately 14 days after vaccination with MenACWY-D. No deaths were reported, and most persons recovered fully. ACIP reviewed the data at the time and determined that the potential small increased risk for GBS post-MenACWY-D vaccination was outweighed by the protection that the vaccine offers against meningococcal disease (92). However, because the risk for recurrence of GBS after meningococcal vaccination was unknown, FDA considered previous history of GBS a contraindication for use of this vaccine (93). A large retrospective cohort study of adolescents aged 11 through 21 years that was conducted during 2005–2008 included approximately 1.4 million persons vaccinated with MenACWY-D (94). In an analysis that took into account the missing data, estimates of the attributable risk for GBS ranged from zero to 1.5 additional cases of GBS per 1 million vaccines within the 6-week period following vaccination (<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf>).

VSD conducts near-real time surveillance for adverse events and tests vaccine safety hypotheses (13). The system collects medical care and vaccination information on approximately 9 million members. VSD uses Rapid Cycle Analysis to monitor vaccine safety in near real-time. Each week, the number of outcomes in vaccinated persons is compared with the expected number of outcomes in the comparison group using maximized sequential probability ratio testing (95). No cases of GBS were identified within 1–42 days following 889,684 vaccine doses of MenACWY-D administered during January 2005–March 2010 (ACIP, unpublished data, 2010).

In June 2010, after reviewing the two safety studies, ACIP voted to remove the precaution for persons with a history of GBS because the benefits of meningococcal vaccination outweigh the risk for recurrent GBS in these persons. A history of GBS continues to be listed as a precaution in the package inserts for MenACWY-D (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf>) and MenACWY-CRM (available at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf>).

[www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf](http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf)). Since the June 2010 ACIP meeting, no specific concerns have been raised about the risk for GBS in persons who both have a history of this condition and have been vaccinated with meningococcal conjugate vaccine (96).

## Safety of Meningococcal Conjugate Vaccine in Pregnancy

During January 1, 2005–June 30, 2010, a total of 80 reports were submitted to VAERS regarding pregnant women or infants born to women who received MenACWY-D during pregnancy. The majority (57.5%) of women were vaccinated in the first trimester (0 through 13 weeks of gestation). Thirty-three (41.3%) reports indicated no adverse events, and the reason for submitting the report to VAERS was vaccine exposure during pregnancy (pregnancy category C)<sup>†</sup>. No maternal deaths were reported. The most common pregnancy-specific adverse event was spontaneous abortion (12 cases; 15%) and the most common nonpregnancy specific adverse event was nausea, with or without vomiting (four cases; 5%). One case of a congenital anomaly (aqueductal stenosis with severe ventriculomegaly in a newborn) was reported. However, no concerning patterns of adverse events after MenACWY-D in pregnancy were identified.

## Postlicensure Safety of Coadministration with Tdap

Two postlicensure studies have evaluated use of Tdap when administered simultaneously or sequentially with MenACWY (97,98). In a clinical trial to evaluate administration of one Tdap product (Boostrix, GSK) and MenACWY-D, immune responses to the meningococcal serogroups and to pertussis, diphtheria, and tetanus were similar regardless of whether the two vaccines were administered simultaneously or separated by 30 days. There were no differences in the safety evaluation in either of the groups. In a postlicensure surveillance study using VSD data, the risk for medically attended adverse events was low (0–2.6 per 10,000 vaccinations) and similar regardless of whether persons received Tdap and MenACWY simultaneously or sequentially (98).

## Cost-Effectiveness Analyses

As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: 1) a

single dose at age 11 years, 2) a single dose at age 15 years, and 3) a dose at age 11 years with a booster dose at age 16 years (ACIP, unpublished data, 2010). The economic costs and benefits of these meningococcal vaccination strategies in adolescents were assessed from a societal perspective (99,100).

A multivariable analysis was performed with a Monte Carlo simulation in which multiple parameters were varied simultaneously over specified probability distributions. These parameters included disease incidence (46%–120% of the 10-year average), case-fatality ratio (34%–131% of the 10-year average), rates of long-term sequelae, acute meningococcal disease costs (i.e., inpatient care, parents' work loss, public health response, and premature mortality costs), lifetime direct and indirect costs of meningococcal disease sequelae (i.e., long-term special education and reduced productivity), and cost of vaccine and vaccine administration (range: \$64–\$114). Vaccination coverage (37%–90%) and initial vaccine efficacy (39%–99%) also were varied for evaluation purposes. The vaccine was assumed to be 93% effective in the first year, and then waning immunity was modeled as a linear decline over the next 9 years unless a booster dose was administered. The vaccine effectiveness of the second dose was assumed to be higher with a slower rate of waning immunity. The results of the cost-effectiveness analysis indicate that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years. However, the number of cases and deaths prevented is substantially higher with the 2-dose strategy (Table 5).

## Rationale for Recommendations for Use of Meningococcal Vaccines

Meningococcal disease can cause severe and devastating illness. Disease incidence is low and has decreased since the late 1990s before widespread vaccination of adolescents with MenACWY. Meningococcal disease occurs in all age groups, with an overall incidence in 2011 of 0.2 cases per 100,000 population. The burden of disease is highest among infants aged <1 year (2.6 cases per 100,000 persons), young adults aged 16 through 21 years (0.4 cases per 100,000 persons), and persons aged ≥65 years (0.3 cases per 100,000 persons) (CDC, unpublished data, 2012). Among infants, disease incidence peaks within the first 6 months of life, and most cases in this age group are caused by serogroup B (see Future Meningococcal Vaccines, Areas for Research, and Public Education). Rates of nasopharyngeal carriage are highest in adolescents and young adults (16,17), and adolescents are likely the main source of transmission of the organism to persons in other age groups.

<sup>†</sup>FDA classification categories available at <http://chemm.nlm.nih.gov/pregnancycategories.htm>



**TABLE 5. Summary of cost-effectiveness analyses of different strategies for adolescent vaccination — United States**

Dosage	Cases averted		Deaths averted		QALY saved		Cost per QALY saved (\$)	
	No.	(Range)	No.	(Range)	No.	(Range)	No.	(Range)
1 dose at 11 yrs	94	(43–165)	11	(5–20)	736	(330–1,130)	256,000	(84,000–650,000)
1 dose at 15 yrs	115	(51–205)	14	(6–25)	850	(390–1,380)	219,000	(63,000–600,000)
1 dose at 11 yrs with booster dose at 16 yrs	184	(92–308)	22	(11–40)	1,442	(610–2,130)	212,000	(67,000–535,000)

**Abbreviation:** QALY = quality-adjusted life years.

**Source:** Unpublished data with updated estimates, Advisory Committee on Immunization Practices (ACIP) meeting, October 2010. Methods described in Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. *Pediatrics* 2005;115:1220–32.

The vaccines licensed currently are recommended routinely for adolescents and other persons at increased risk for meningococcal disease. After licensure of the first MenACWY vaccine in 2005, the initial supply of vaccine was not sufficient to vaccinate all adolescents. ACIP prioritized vaccination for persons aged 11 or 12 years, persons entering high school, and first-year college students living in residence halls. Two years later, in 2007, after reviewing information on the adequacy of vaccine supply, ACIP expanded its recommendation for routine 1-dose vaccination at the earliest opportunity for all adolescents aged 11 through 18 years. At the time, some experts predicted that the vaccine would be effective for up to 10 years, providing protection through the period of highest risk in late adolescence and early adulthood.

Since the 2005 ACIP recommendations, additional data have led to improved understanding of meningococcal conjugate vaccines, including new data on duration of vaccine-induced immunity. Antibody persistence studies indicate that circulating antibody declines 3 to 5 years after a single dose of MenACWY. In addition, results from a vaccine effectiveness study demonstrate waning effectiveness, and many adolescents are not protected 5 years after vaccination. ACIP concluded that a single dose of meningococcal conjugate vaccine administered at age 11 or 12 years is unlikely to protect most adolescents through the period of increased risk at ages 16 through 21 years. On the basis of this information, in 2010, ACIP considered two options to optimize protection through late adolescence into early adulthood: 1) moving the single recommended dose to age 15 years or 2) retaining the recommended dose at ages 11 or 12 years and adding a booster dose at age 16 years. The benefits of the booster dose and a desire to continue to protect younger adolescents prompted the recommendation for a routine booster dose at age 16 years (7).

In 2010, ACIP revised the recommendations for dosing regimens (e.g., primary series and booster doses) for persons who have functional or anatomic asplenia, who have persistent complement component deficiencies, or who have HIV infection and are otherwise recommended to be vaccinated. For these immunosuppressed persons, a 2-dose primary series was recommended instead of a single dose (7). For persons with

persistent complement component deficiency, a 2-dose primary series will help achieve the high levels of SBA needed to confer protection in the absence of effective opsonization. For persons with asplenia or HIV, a 2-dose primary series will increase the likelihood of a sufficient primary immune response. Booster doses after primary vaccination are important for persons with prolonged increased risk (persons with asplenia, persons with complement component deficiencies, and microbiologists) to ensure high levels of SBA are maintained over time.

In 2011 and 2012, ACIP voted to recommend meningococcal vaccination for children aged 2 through 23 months who are at increased risk for disease. ACIP does not recommend routine vaccination of children aged  $\leq 10$  years. The number of infants and young children who are or will be at increased risk for meningococcal disease is limited. ACIP reviewed the burden of meningococcal disease among infants and children aged  $\leq 10$  years. In the United States, during 1993–2011, average annual rates of meningococcal disease were higher among children aged  $\leq 59$  months. However, approximately 60% of disease among children aged  $\leq 59$  months is caused by serogroup B *N. meningitidis* which is not prevented by Hib-MenCY-TT or MenACWY-D. In addition, the highest incidence in the first 5 years of life occurs in infants aged 0 through 6 months, many of whom are too young to have received the minimum 2 or 3 doses of vaccine that likely are needed to provide protection. Of the 205 cases of meningococcal disease in children aged  $< 59$  months that occur annually, it is estimated that a universal infant meningococcal vaccination program would prevent 40–50 cases (approximately 25% of cases in this age group) (CDC, unpublished data, 2012). The epidemiology of meningococcal disease is dynamic, and rates of disease could increase in the future requiring a reassessment of immunization strategy.

## Recommendations for Use of Meningococcal Vaccines

### Routine Vaccination of Adolescents

ACIP recommends routine administration of a MenACWY vaccine for all persons aged 11 through 18 years (Table 6). A single



**TABLE 6. Recommended meningococcal vaccines for use in children and adults — Advisory Committee on Immunization Practices (ACIP), United States, 2012**

Age group	Vaccine	Status
2 mos–10 yrs	MenACWY-D (Menactra, Sanofi)*	Not routinely recommended; see Table 7 for persons at increased risk
	MenACWY-CRM (Menveo, Novartis)†	Not routinely recommended; see Table 7 for persons at increased risk
	HibMenCY-TT (MenHibrix, GSK)§	Not routinely recommended; see Table 7 for persons at increased risk
11–21 yrs	MenACWY-D or MenACWY-CRM	Primary: <ul style="list-style-type: none"> <li>• Age 11–12 yrs, 1 dose</li> <li>• Age 13–18 yrs, 1 dose if not vaccinated previously</li> <li>• Age 19–21 yrs, not routinely recommended but may be administered as catch-up vaccination for those who have not received a dose after their 16th birthday</li> </ul> Booster: <ul style="list-style-type: none"> <li>• 1 dose recommended if first dose administered before 16th birthday</li> </ul>
	MenACWY-D or MenACWY-CRM	Not routinely recommended; see Table 7 for persons at increased risk
22–55 yrs	MPSV4, MenACWY-D, or MenACWY-CRM	Not routinely recommended; see Table 7 for persons at increased risk
≥56 yrs	MPSV4, MenACWY-D, or MenACWY-CRM	Not routinely recommended; see Table 7 for persons at increased risk

**Source:** Adapted from American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove, IL: American Academy of Pediatrics; 2012:500–9.

\* Licensed only for persons aged 9 months–55 years.

† Licensed only for persons aged 2–55 years. Under investigation for use at ages 2, 4, 6, and 12–15 months.

§ Licensed only for children aged 6 weeks–18 months.

dose of vaccine should be administered at age 11 or 12 years, and a booster dose should be administered at age 16 years. Adolescents who receive their first dose at age 13 through 15 years should receive a booster dose at age 16 through 18 years. The minimum interval between doses of MenACWY is 8 weeks. Adolescents who receive a first dose after their 16th birthday do not need a booster dose unless they become at increased risk for meningococcal disease. Persons aged 19 through 21 years are not recommended routinely to receive MenACWY. MenACWY may be administered up to age 21 years as catch-up vaccination for those who have not received a dose after their 16th birthday. Health-care personnel should use every opportunity to provide the booster dose when indicated, regardless of the vaccine brand used for the previous dose or doses.

## Recommendations for Special Populations and Persons at Increased Risk for Meningococcal Disease

Persons at increased risk for meningococcal disease also are recommended for routine meningococcal vaccination (Tables 6 and 7). Vaccine product, number of doses, and

booster dose recommendations are based on age and risk factor and are described below in detail for each risk group. In general:

- Infants aged 2 through 18 months.** Routine vaccination with Hib-MenCY-TT (4-dose primary series) is recommended for infants aged 2 through 18 months who are at increased risk for meningococcal disease. The first dose of Hib-MenCY-TT may be administered as early as age 6 weeks. The fourth dose may be administered as late as age 18 months. Catch-up vaccination for Hib-MenCY-TT is the same as for other Hib-containing vaccines (available at <http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html>) with the following exception. If the first dose of Hib-MenCY-TT is administered at or after 12 months of life, 2 doses should be given at least 8 weeks apart. Hib-MenCY-TT can be co-administered with other routine infant vaccinations, including 13-valent pneumococcal conjugate vaccine. Hib-MenCY-TT should not be co-administered with other Hib-containing vaccines. Infants at increased risk who are vaccinated with Hib-MenCY-TT do not need to be vaccinated with MenACWY until the first booster dose (3 years after completion of the Hib-MenCY-TT series), unless another indication is present (e.g., travel to countries in which meningococcal disease is hyperendemic or epidemic).
- Persons aged 9 months through 55 years.** Persons aged 9 months through 55 years at increased risk for meningococcal disease should receive MenACWY. Infants aged 9 through 23 months are recommended to receive a 2-dose primary series with a dosing interval of 12 weeks. Infants who have been vaccinated with Hib-MenCY-TT do not need to receive MenACWY unless they are traveling to areas with high endemic rates of meningococcal disease and require protection with Serogroups A and W. Persons aged 2 through 55 years are recommended to receive a single dose or a 2-dose primary series based on the indication for vaccination.
- Persons aged ≥56 years.** MPSV4 is the only licensed meningococcal vaccine for adults aged ≥56 years and is immunogenic in older adults. For adults who have received MenACWY previously, limited data demonstrate a higher antibody response after a subsequent dose of MenACWY compared with a subsequent dose of MPSV4. For meningococcal vaccine-naïve persons aged ≥56 years who anticipate requiring a single dose of meningococcal vaccine (e.g., travelers and persons at risk as a result of a community outbreak), MPSV4 is preferred. For persons now aged ≥56 years who were vaccinated previously with MenACWY and are recommended for revaccination or for whom multiple doses are anticipated (e.g., persons with asplenia and microbiologists), MenACWY is preferred.

**TABLE 7. Recommended immunization schedule and intervals for persons at increased risk for meningococcal disease — Advisory Committee on Immunization Practices (ACIP), United States, 2012\***

Age group	Subgroup	Primary vaccination	Booster dose <sup>†</sup>
2–18 mos with high-risk conditions <sup>§</sup>	Children who: <ul style="list-style-type: none"> <li>• have persistent complement deficiencies</li> <li>• have functional or anatomic asplenia</li> <li>• are at risk during a community outbreak attributable to a vaccine serogroup</li> </ul>	4 doses of Hib-MenCY-TT (MenHibrix), at 2, 4, 6, and 12–15 months	Person remains at increased risk and completed the primary dose or series at age: <ul style="list-style-type: none"> <li>• <b>2 mos–6 yrs:</b> Should receive additional dose of MenACWY 3 yrs after primary immunization; boosters should be repeated every 5 yrs thereafter</li> <li>• <b>≥7 yrs:</b> Should receive additional dose of MenACWY 5 yrs after primary immunization; boosters should be repeated every 5 yrs thereafter</li> </ul>
9–23 mos with high-risk conditions <sup>¶</sup>	Children who: <ul style="list-style-type: none"> <li>• have persistent complement deficiencies</li> <li>• travel to or are residents of countries where meningococcal disease is hyperendemic or epidemic</li> <li>• are at risk during a community outbreak attributable to a vaccine serogroup</li> </ul>	2 doses of MenACWY-D (Menactra), 12 weeks apart**	
2–55 yrs with high-risk conditions and not vaccinated previously	Persons who: <ul style="list-style-type: none"> <li>• have persistent complement deficiencies</li> <li>• have functional or anatomic asplenia</li> <li>• have HIV, if another indication for vaccination exists</li> </ul>	2 doses of MenACWY, 8–12 weeks apart <sup>††</sup>	
	Persons who: <ul style="list-style-type: none"> <li>• are first-year college students aged ≤21 years living in residential housing</li> <li>• travel to or are residents of countries where meningococcal disease is hyperendemic or epidemic</li> <li>• are at risk during a community outbreak attributable to a vaccine serogroup</li> <li>• are microbiologists routinely exposed to isolates of <i>Neisseria meningitidis</i></li> </ul>	1 dose of MenACWY <sup>††</sup>	

**Source:** Adapted from American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove, IL: American Academy of Pediatrics; 2012: 500–9.

\* Includes persons who have persistent complement deficiencies (e.g., C5–C9, properdin, factor H, or factor D), and anatomic or functional asplenia; travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic; and persons who are part of a community outbreak of a vaccine-preventable serogroup.

† If the person remains at increased risk for meningococcal disease.

§ Infants and children who received Hib-MenCY-TT and are travelling to areas with high endemic rates of meningococcal disease such as the African “meningitis belt” are not protected against serogroups A and W-135 and should receive a quadrivalent meningococcal vaccination licensed for children aged ≥9 months prior to travel.

¶ Because of high risk for invasive pneumococcal disease, children with functional or anatomic asplenia should not be immunized with MenACWY-D (Menactra) before age 2 years to avoid interference with the immune response to the pneumococcal conjugate vaccine (PCV) series.

\*\* If an infant is receiving the vaccine prior to travel, 2 doses may be administered as early as 8 weeks apart.

†† If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.

### Persons Who Have Persistent Complement Component Deficiencies (C3, C5-9, Properdin, Factor D, and Factor H)

- A 2-dose primary series of MenACWY administered 8–12 weeks apart, is recommended for persons aged 9 months through 55 years with persistent deficiencies of the late complement component pathway.
- A 4-dose primary series of Hib-MenCY-TT can be administered to infants aged 2 through 18 months with known persistent deficiencies of the late complement component pathway.
- A booster dose should be administered every 5 years; children who receive the primary series before their seventh birthday should receive the first booster dose in 3 years and subsequent doses every 5 years.

### Persons Who Have Anatomic or Functional Asplenia

- A 2-dose primary series of MenACWY administered 8–12 weeks apart is recommended for persons aged 2 through 55 years with anatomic or functional asplenia.
- A 4-dose primary series of Hib-MenCY-TT is recommended for infants aged 2 through 18 months.
- Infants aged 19 through 23 months who have not received Hib-MenCY-TT should defer vaccination with MenACWY until age 2 years and completion of the PCV-13 series.
- A booster dose should be administered every 5 years; children who receive the primary series before their seventh birthday should receive the first booster dose in 3 years and subsequent doses every 5 years.

### Microbiologists Who Are Exposed Routinely to Isolates of *N. meningitidis*

- Microbiologists routinely exposed to isolates of *N. meningitidis* are recommended to receive a single dose of MenACWY. A booster dose should be administered every 5 years if exposure is ongoing.

### Persons Who Travel to or Reside in Countries in Which Meningococcal Disease Is Hyperendemic or Epidemic, Particularly if Contact with the Local Population Will Be Prolonged

- For international travelers, vaccination is recommended for those visiting the parts of sub-Saharan Africa known as the “meningitis belt” during the dry season (December–June).
- International travelers should receive a booster dose of MenACWY if the last dose was administered 5 or more years previously. Vaccination in the 3 years before the date of travel is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj.
- Children aged 9 through 23 months can receive the second dose as early as 8 weeks after the first dose before travel.
- Infants and children who received Hib-MenCY-TT and are travelling to areas with high endemic rates of meningococcal disease are not protected against serogroups A and W and should receive 1 or 2 doses of a quadrivalent meningococcal vaccination licensed for children aged  $\geq 9$  months before travel (dependent on age at vaccination and product used [see Table 7]).
- Advisories for travelers to other countries are issued by CDC when epidemics of meningococcal disease caused by vaccine-preventable serogroups are detected. Travelers’ health information is available from CDC toll free at telephone 1-877-394-8747 (1-877-FYI-TRIP) or at <http://www.cdc.gov/travel>. Further information concerning geographic areas for which vaccination is recommended can be obtained from international health clinics for travelers and state health departments.

### Persons with Human Immunodeficiency Virus

- HIV infection is not an indication for routine MenACWY vaccination.
- Persons with HIV infection who are recommended routinely to receive vaccine (i.e., persons aged  $\geq 9$  months at increased risk for meningococcal disease and all persons aged 11 through 18 years) should receive a 2-dose primary series, administered 8–12 weeks apart, because evidence suggests that persons with HIV do not respond optimally to a single dose (3,4).

### First-Year College Students Living in Residence Halls

- First-year college students living in residence halls should receive at least 1 dose of MenACWY before college entry. The preferred timing of the most recent dose is on or after their 16th birthday.
- If only 1 dose of vaccine was administered before the 16th birthday, a booster dose should be administered before enrollment.
- Some schools, colleges, and universities have policies requiring vaccination against meningococcal disease as a condition of enrollment for either incoming first-year students living in residence halls or all incoming first-year students. For ease of program implementation, persons aged  $\leq 21$  years should have documentation of receipt of meningococcal conjugate vaccine not more than 5 years before enrollment.

### Outbreaks of Meningococcal Disease

MenACWY or Hib-MenCY-TT is recommended for use in control of outbreaks caused by vaccine-preventable serogroups (A, C, Y, and W-135) of *N. meningitidis* (Appendix B). An outbreak is defined by the occurrence of at least three confirmed or probable primary cases of meningococcal disease caused by the same serogroup in  $\leq 3$  months, with a resulting primary attack rate of  $\geq 10$  cases per 100,000 population. For calculation of this threshold, population-based rates are used rather than age-specific attack rates. MenACWY is preferred if the population targeted for vaccination includes age groups for which MenACWY is licensed (i.e., 9 months through 55 years). Detailed recommendations on evaluation and management of suspected outbreaks of meningococcal disease are provided (Appendix B).

### Children Aged 2 Months through 10 Years Not at Increased Risk for Meningococcal Disease

Routine vaccination against meningococcal disease is not recommended for children aged 2 months through 10 years. Hib-MenCY-TT is licensed as a 4-dose primary series for children aged 6 weeks through 18 months. Hib-MenCY-TT can be administered in any infant for routine vaccination against Hib and will offer some protection against serogroups C and Y meningococcal disease; 4 doses of Hib-MenCY-TT fulfill the primary series and booster dose Hib immunization recommendations. If the reason for use of Hib-MenCY-TT vaccine is to achieve protection against serogroups C and Y, it should be used for all 4 doses of Hib vaccine. Infants and children who received Hib-MenCY-TT and are travelling to areas with high endemic rates of meningococcal disease such as the “meningitis belt” are not protected against serogroups A and W-135 and should receive a quadrivalent meningococcal conjugate vaccine licensed for children aged  $\geq 9$  months before travel.

MenACWY-D is licensed as a 2-dose primary series for children aged 9 through 23 months and as a single dose for children ages 2 through 10 years. MenACWY-CRM is licensed as a single dose for children aged 2 through 10 years. Children who receive Hib-MenCY-TT, MenACWY, or both Hib-MenCY-TT and MenACWY before their 10th birthday should receive the routinely recommended doses at age 11 or 12 years and at age 16 years.

## Administration

MenACWY-D, MenACWY-CRM, and Hib-MenCY-TT vaccines are administered intramuscularly, and MPSV4 is administered subcutaneously. Individual doses of all vaccines are 0.5 mL. In persons aged 2 through 55 years, MenACWY and MPSV4 vaccines can be administered concomitantly with other vaccines, but at a different anatomic site, if feasible. Because of limited data suggesting immunologic blunting of the meningococcal vaccine, MenACWY-D should be administered to children aged 2 through 6 years either before, at the same time, or more than 6 months after receipt of DTaP. If MenACWY-D is administered inadvertently in the 6 months after receipt of DTaP, the dose does not need to be repeated. MenACWY-CRM may be administered at any time in relation to DTaP administration. If a child is traveling to a high-risk area or is part of a community outbreak, waiting to administer MenACWY-D following receipt of DTaP is not recommended, even if there may be blunting. There is no evidence of immunologic blunting between Tdap and MenACWY when either MenACWY-D or MenACWY-CRM is administered following administration of Tdap.

In children aged 2 through 18 months, Hib-MenCY-TT can be administered concomitantly with other vaccines, but at a different anatomic site, if feasible. In children aged 9 through 23 months, MenACWY-D can be administered with other vaccines concomitantly in healthy children at different anatomic sites, if feasible. Children with asplenia should not receive MenACWY-D concomitantly with PCV13; if MenACWY-D is used in persons with asplenia, it should be administered at least 4 weeks after completion of all PCV13 doses.

All health-care personnel administering vaccinations should be aware of the potential for syncope after vaccination, especially among adolescents, and should take appropriate measures to prevent potential injuries. If syncope occurs, the vaccine recipient should be observed until symptoms resolve. Providers should strongly consider observing patients for 15 minutes after they are vaccinated (97).

## Precautions and Contraindications

Vaccination with MenACWY, MPSV4, or Hib-MenCY-TT is contraindicated among persons known to have a severe allergic

reaction to any component of the vaccine, including diphtheria or tetanus toxoid. ACIP does not consider a history of GBS to be a contraindication or precaution for meningococcal vaccination.

Recommended vaccinations can be administered to persons with minor acute illness (e.g., diarrhea or mild upper-respiratory tract infection with or without low grade fever). Vaccination should be deferred for persons with moderate or severe acute illness until the person's condition improves (101). Because MenACWY, MPSV4, and Hib-MenCY-TT are inactivated vaccines, they can be administered to persons who are immunosuppressed as a result of disease or medications; however, response to the vaccine might be less than optimal.

## Vaccinating During Pregnancy and Breastfeeding

To date, no randomized, controlled clinical trials have been conducted primarily to evaluate use of MPSV4 or MenACWY vaccines in pregnant or lactating women. VAERS reports of exposure to MPSV4 during pregnancy have not identified adverse effects among either pregnant women or newborns of women vaccinated during pregnancy. From VAERS reports available for women found to be pregnant at the time of MenACWY-D vaccination, no major safety concerns associated with vaccination have been identified in the mother or fetus. Pregnancy should not preclude vaccination with MenACWY or MPSV4, if indicated. Women of childbearing age who become aware that they were pregnant at the time of MenACWY vaccination should contact their health-care provider or the vaccine manufacturer so that their experience might be captured in the manufacturer's registry of vaccination during pregnancy. Any adverse event following receipt of MenACWY, MPSV4 or Hib-MenCY-TT vaccine should be reported to VAERS at telephone 1-800-822-7967 or at <http://vaers.hhs.gov/index>.

## Future Meningococcal Vaccines, Areas for Research, and Public Education

MenACWY vaccines were licensed on the basis of data regarding safety and short-term immunogenicity. However, immunogenicity data alone are insufficient to predict vaccine effectiveness and herd immunity effect, which depends largely on the ability of vaccine to alter transmission patterns. Multiple changes to the recommendations have been made since 2005 (Box 1); the effect of these changes needs to be monitored over time for their effectiveness and impact on disease to be assessed.

Because serogroup B capsular polysaccharide is poorly immunogenic in humans, vaccine development for serogroup B *N. meningitidis* has focused on common proteins, including the



outer membrane vesicles (OMV) of specific epidemic strains. Efficacy of OMV vaccines has been demonstrated among older children and adults but not among infants and young children, in whom rates of disease are highest (102–105). In addition, the variability in OMV strains causing endemic disease will likely limit their usefulness in the United States (106,107).

Two vaccines developed to prevent serogroup B vaccine are in late-stage clinical development in the United States. A multicomponent serogroup B meningococcal vaccine (4CMenB), approved for use in Europe by the European Medicines Agency in January 2013, was developed by sequencing the meningococcal B genome and testing surface antigens for their ability to elicit an immunogenic response. Three novel antigens identified, factor-H binding protein (fHbp), *Neisserial* adhesion A (NadA), and *Neisseria* heparin binding antigen (NHBA), were combined with OMV from the New Zealand epidemic strain NZ98/254 (108). The second vaccine, bivalent recombinant lipoprotein 2086 vaccine, contains two families of the same protein, fHbp, as 4CMenB (109). When these vaccines are licensed, vaccines to prevent all five serogroups that cause most meningococcal disease worldwide will be available for the first time. However, extensive research is needed to understand better how to conduct optimal implementation of noncapsular based meningococcal vaccines.

Although the signs and symptoms of meningococcal disease are frequently nonspecific, increasing awareness for meningococcal disease can result in earlier medical care-seeking behavior and improved clinical outcomes. In addition, educating adolescents and their parents about the benefits of receiving MenACWY is key to preventing a substantial number of cases of meningococcal disease. Finally, educating policy makers and the general public about the benefits of receiving MenACWY vaccine might improve vaccination coverage rates and substantially decrease the burden of meningococcal disease in the United States.

## References

1. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2005;54(No. RR-7).
2. Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. *Infect Immun* 2004;72:332–7.
3. Siberry GK, Warshaw MG, Williams PL, et al. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 2012;31:47–52.
4. Siberry GK, Williams PL, Lujan-Zilbermann J, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. *Pediatr Infect Dis J* 2010;29:391–6.
5. CDC. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. *MMWR* 2007;56:794–5.
6. CDC. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use—Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR* 2010;59:273.
7. CDC. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR* 2011;60:72–6.
8. CDC. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2–10 years at increased risk for invasive meningococcal disease. *MMWR* 2007;56:1265–6.
9. CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. *MMWR* 2009;58:1042–3.
10. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. *MMWR* 2011;60:1391–2.
11. CDC. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. *MMWR* 2013;62:52–4.
12. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. *Pediatr Infect Dis J* 2004;23:287–94.
13. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. *Pediatrics* 2011;127(Suppl 1):S45–53.
14. Schuchat A, Hilger T, Zell E, et al. Active bacterial core surveillance of the emerging infections program network. *Emerg Infect Dis* 2001;7:92–9.
15. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. *Clin Infect Dis* 2010; 50:184–91.
16. Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of *Neisseria meningitidis* in a randomly sampled population. *J Clin Microbiol* 1994;32:323–30.
17. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. *Lancet Infect Dis* 2010;10:853–61.
18. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. *J Pediatr* 1981;99:540–5.
19. Kirsch EA, Barton RP, Kitcahen L, Giroir BP. Pathophysiology, treatment and outcome of meningococemia: a review and recent experience. *Pediatr Infect Dis* 1996;15:967–79.
20. Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE. Increased case-fatality rate associated with outbreaks of *Neisseria meningitidis* infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. *Clin Infect Dis* 2006;43:49–54.

21. CDC. Outbreak of meningococcal disease associated with an elementary school—Oklahoma, March 2010. *MMWR* 2012;61:217–21.
22. CDC. National vaccination coverage among adolescents aged 13–17 years—United States, 2006. *MMWR* 2007;56:885–8.
23. CDC. National vaccination coverage among adolescents aged 13–17 years—United States, 2006. *MMWR* 2007;56:885–8.
24. Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. *Pediatr Infect Dis J* 2011;30:451–5.
25. MacNeil JR, Cohn AC. Meningococcal vaccine effectiveness [Presentation]. International Pathogenic *Neisseria* Conference, Wurzburg, Germany; September 10–14, 2012.
26. Diermayer M, Hedberg K, Hoesly FC, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. *JAMA* 1999;281:1493–7.
27. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. *Clin Microbiol Rev* 1991;4:359–95.
28. Platonov AE, Beloborodov VB, Vershinina IV. Meningococcal disease in patients with late component deficiency: studies in the U.S.S.R. *Medicine (Baltimore)* 1993;72:374–92.
29. Francke EL, Neu HC. Postsplenectomy infection. *Surg Clin North Am* 1981;61:135–55.
30. Fischer M, Hedberg K, Cardoso P, et al. Tobacco smoke as a risk factor for meningococcal disease. *Pediatr Infect Dis J* 1997;16:979–83.
31. Fischer M, Harrison L, Farley M, et al. Risk factors for sporadic meningococcal disease in North America [Abstract 552 Fr]. In: Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado; November 12–15, 1998.
32. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. *Ann Intern Med* 1995;123:937–9.
33. Cartwright KA, Jones DM, Smith AJ, Stuart JM, Kaczmarek ER, Palmer SR. Influenza A infection and meningococcal disease. *Lancet* 1991;338:554–7.
34. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. *JAMA* 1988;260:2686–9.
35. Stanwell-Smith RE, Stuart JM, Hughes AO, Robinson P, Griffin MB, Cartwright K. Smoking, the environment and meningococcal disease: a case control study. *Epidemiol Infect* 1994;112:315–28.
36. Stuart JM, Cartwright KA, Dawson JA, Richard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. *Community Med* 1988;10:139–46.
37. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. *J Infect Dis* 1999;180:1894–901.
38. CDC. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. *MMWR* 1993 (No. SS-2);42:21–30.
39. Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. *J Clin Microbiol* 2005;43:4811–4.
40. CDC. Laboratory-acquired meningococcal disease—United States, 2000. *MMWR* 2002;51:141–4.
41. Couldwell DL. Invasive meningococcal disease and HIV coinfection. *Commun Dis Intell* 2001;25:279–80.
42. Harris CM, Wu HM, Cohn AC, Clark TA, Messonnier NE. HIV infection in meningococcal disease patients, United States, 2000–2008 [Presentation]. 48th Annual Meeting of the Infectious Diseases Society of America, Vancouver, British Columbia, Canada; October 21–24, 2010.
43. Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. *JAMA* 1999;281:1906–10.
44. Bruce M, Rosenstein NE, Capparella J, Perkins BA, Collins MJ. Meningococcal disease in college students. In: Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA: Infectious Diseases Society of America; 1999:276.
45. Neal KR, Nguyen-Van-Tam J, Monk P, O'Brien SJ, Stuart J, Ramsay M. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodations. *Epidemiol Infect* 1999;122:351–7.
46. Froeschle J. Meningococcal disease in college students. *Clin Infect Dis* 1999;29:215–6.
47. CDC. Meningococcal disease and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2000;49(No. RR-7):13–20.
48. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. *J Exp Med* 1969;129:1307–26.
49. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. *J Exp Med* 1969;129:1367–84.
50. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. *Clin Diagn Lab Immunol* 2001;8:616–23.
51. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection—serum bactericidal antibody activity. *Vaccine* 2005;23:2222–7.
52. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. *Infect Immun* 2001;69:1568–73.
53. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. *Clin Diagn Lab Immunol* 2003;10:780–6.
54. Stein K. Thymus-independent and thymus-dependent responses to polysaccharide antigens. *J Infect Dis* 1992;165 (Suppl):S49–52.
55. Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of *H. influenzae* type b-*N. meningitidis* C/Y conjugate vaccine in infants. *Pediatrics* 2011;127:e1375–85.
56. Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel *Haemophilus influenzae* type b and *Neisseria meningitidis* serogroups C and Y—tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. *Human Vaccines* 2011;7:258–64.
57. Nolan T, Richmond P, Marshall H, et al. Immunogenicity and safety of an investigational combined *Haemophilus influenzae* type B-*Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine. *Pediatr Infect Dis J* 2011;30:190–6.
58. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. *J Clin Invest* 1975;56:1536–47.
59. Peltola H, Makela PH, Kayhty H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. *N Engl J Med* 1977;297:686–91.
60. Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH. Serum antibodies to capsular polysaccharide vaccine of group A *Neisseria meningitidis* followed for three years in infants and children. *J Infect Dis* 1980;142:861–8.

61. Rosenstein N, Levine O, Taylor J, et al. Efficacy of meningococcal vaccine and barriers to vaccination. *JAMA* 1998;279:435–9.
62. Pinner RW, Onyango F, Perkins BA, et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. *J Infect Dis* 1992;166:359–64.
63. Taunay AE, Feldman RA, Bactos CO, Galvao PA, de Moraes JS, Castro IO. Assessment of the protection conferred by antigroup C meningococcal polysaccharide vaccine to 6 to 36 month-old children [Portuguese]. *Rev Inst Adolfo Lutz* 1978;38:77–82.
64. Cochi SL, Markowitz L, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. *Int J Epidemiol* 1987;16:91–7.
65. Griffis JM, Brandt BL, Broude DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. *Infect Immun* 1982;37:205–8.
66. Armand J, Arminjon F, Mynard MC, Lefaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serologic evaluation. *J Biol Stand* 1982;10:335–9.
67. Ambrosch F, Wiedermann G, Crooy P, George AM. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. *Bull WHO* 1983;61:317–9.
68. Borrow R, Joseph H, Andrews N, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. *Vaccine* 2001;19:1129–32.
69. MacLennan J, Obara S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. *Vaccine* 1999;17:3086–93.
70. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugates vs. plain meningococcal C polysaccharide vaccine in toddlers. *JAMA* 1998;280:1685–9.
71. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. *J Infect Dis* 1998;178:870–4.
72. Goldblatt D BR, Miller E. Natural and vaccine-induced immunity and immunologic memory to *Neisseria meningitidis* serogroup C in young adults. *J Infect Dis* 2002;397–400.
73. de Voer RM, van der Klis FR, Engels CW, et al. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. *Vaccine* 2009;27:6974–82.
74. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. *J Infect Dis* 2006;194:1745–52.
75. Cohn AC, Meyer S, MacNeil J, et al. Impact of quadrivalent meningococcal conjugate vaccine (MenACWY) coverage on disease incidence—United States, 2004–2010 [Presentation]. International Pathogenic *Neisseria* Meeting, Wurzburg, Germany; September 10–14, 2012.
76. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. *Lancet* 2004;364:365–7.
77. Ramsay ME. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. *BMJ* 2003;326:365–6.
78. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. *J Infect Dis* 2008;197:737–43.
79. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. *Clin Vaccine Immunol* 2010;17:840–7.
80. Pollard A, Perrett K, Beverley P. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. *Nature Rev Immunol* 2009;9:213–9.
81. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. *Arch Pediatr Adolesc Med* 2005;159:907–13.
82. Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. *J Infect Dis* 2006;193:821–8.
83. Gill C, Baxter R, Anemona A, Ciavarrò G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. *Human Vaccines* 2010;6:881–7.
84. Gill C, Baxter R, Juszcak P, Karsten A, Odrliin T, Dull PM, eds. The persistence of immune responses and boosting in adolescents three years after administration of Menveo or Menactra to healthy adolescents. Denver, CO: Pediatric Academic Society; 2011.
85. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent *Neisseria meningitidis*-diphtheria toxoid conjugate vaccine. *Pediatr Infect Dis J* 2004;23:490–7.
86. Granoff DM, Morgan A, Welsch JA. Immunogenicity of an investigational quadrivalent *Neisseria meningitidis*-diphtheria toxoid conjugate vaccine in 2-year old children. *Vaccine* 2005;23:4307–14.
87. Miller JM. Persistence of antibodies after vaccination of infants with HibMenCY. San Diego, CA: Infectious Disease Society of America; 2012.
88. CDC. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR* 2011;60:1018–9.
89. CDC. Syncope after vaccination—United States, January 2005–July 2007. *MMWR* 2008;57:457–60.
90. CDC. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, June–July 2005. *MMWR* 2005;54:1023–5.
91. CDC. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, June 2005–September 2006. *MMWR* 2006;55:1120–4.
92. Cho B, Clark, TA, Messonnier, NE. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach. *Vaccine* 2010;28:817–22.
93. CDC. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, October 2005–February 2006. *MMWR* 2006;55:364–6.
94. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. *Pharmacoepidemiol Drug Sa* 2012 doi: 10.1002/pds.3321.
95. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. *Pediatrics* 2011;127(Suppl 1):S54–64.

96. Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP, Network C. Recurrent Guillain-Barré syndrome following vaccination. *Clin Infect Dis* 2012;54:800–4.
97. Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of coadministered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. *Vaccine* 2011;29:1017–22.
98. Jackson LA, Yu O, Nelson J, et al. Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. *Vaccine* 2009;27:4912–6.
99. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. *Clin Infect Dis* 2008;46:1–13.
100. Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. *Pediatrics* 2005;115:1220–32.
101. CDC. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2011;60(No. RR-2).
102. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. *Lancet* 1992;340(8827):1074–8.
103. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. *Vaccine* 1995;13:821–9.
104. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. *Lancet* 1998;338(8775):1093–6.
105. Sierra GVG, Campo HC, Varcacel NM, et al. Vaccine against group B *Neisseria meningitidis*: protection trial and mass vaccination results in Cuba. *NIPH Ann* 1991;14:195–210.
106. Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (Por A) outer membrane proteins. *Vaccine* 1999;17:2612–9.
107. Tondella MLC, Popovic T, Rosenstein NE, et al. Distribution of *Neisseria meningitidis* serogroup B serosubtypes and serotypes circulating in the United States. *J Clin Microbiol* 2000;38:2402–7.
108. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. *JAMA* 2012;307:573–82.
109. Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 2012;12:597–607.



## APPENDIX A

## Antimicrobial Chemoprophylaxis

Antimicrobial chemoprophylaxis of close contacts of a patient with invasive meningococcal disease is important to prevent secondary cases (Table). Close contacts include 1) household members (1), 2) child-care center contacts (2,3), and 3) anyone directly exposed to the patient's oral secretions (e.g., through kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management) in the 7 days before symptom onset. Health-care personnel should receive chemoprophylaxis if they were managing an airway or exposed to respiratory secretions of a patient with meningococcal disease. For travelers, antimicrobial chemoprophylaxis should be considered for any passenger who had direct contact with respiratory secretions from an index-patient or for anyone seated directly next to an index-patient on a prolonged flight (i.e., one lasting  $\geq 8$  hours) (4). The attack rate for household contacts exposed to patients who have sporadic meningococcal disease was estimated to be four cases/1,000 persons exposed, which is 500–800 times greater than the rate for the total population (5). In the United Kingdom, the attack rate among health-care personnel exposed to patients with meningococcal disease was 25 times higher than among the general population (6).

Chemoprophylaxis is not recommended for close contacts of patients with evidence of *Neisseria meningitidis* only in nonsterile sites such as an oropharyngeal swab, endotracheal secretions, or conjunctival swab. Reports of secondary cases after close contact to persons with noninvasive pneumonia or conjunctivitis are rare; there is no evidence of substantive excess risk (7–9). Furthermore, there is no indication to treat persons who are asymptomatic nasopharyngeal carriers.

Because the rate of secondary disease for close contacts is highest immediately after onset of disease in the index patient, antimicrobial chemoprophylaxis should be administered as soon as possible (ideally <24 hours after identification of the index patient). Conversely, chemoprophylaxis administered >14 days after exposure to the index patient is probably of limited or no value. Oropharyngeal or nasopharyngeal cultures are not helpful in determining the need for chemoprophylaxis and might delay institution of this preventive measure unnecessarily.

Rifampin, ciprofloxacin, and ceftriaxone are 90%–95% effective in reducing nasopharyngeal carriage of *N. meningitidis* and are all acceptable antimicrobial agents for chemoprophylaxis (10–13). Although sporadic resistance to rifampin and ciprofloxacin have been reported worldwide, meningococcal resistance to chemoprophylaxis antibiotics remains rare in the United States. Clinicians should report suspected chemoprophylaxis failures to their public health departments. Systemic antimicrobial therapy of meningococcal disease with agents other than ceftriaxone or other third-generation cephalosporins might not eradicate nasopharyngeal carriage of *N. meningitidis* reliably. If other agents have been used for treatment, the index patient should receive chemoprophylactic antibiotics for eradication of nasopharyngeal carriage before being discharged from the hospital (14).

Although azithromycin is not recommended for use as a first-line chemoprophylaxis agent, one study has reported that a single 500-mg oral dose of azithromycin was effective in eradicating nasopharyngeal carriage of *N. meningitidis* (15). Azithromycin, in addition to being safe and easy to administer, is also available in a suspension form and is approved for use among children. Azithromycin has been recommended for prophylaxis in the rare circumstance of sustained ciprofloxacin resistance in a local community; however, further evaluation is warranted of both the effectiveness of azithromycin in eradicating carriage of *N. meningitidis* and potential for development of microbial resistance (15).

**TABLE. Recommended chemoprophylaxis regimens for protection against meningococcal disease — Advisory Committee on Immunization Practices (ACIP), United States, 2012**

Drug	Age group	Dosage	Duration and route of administration*
Rifampin <sup>†</sup>	Children aged <1 mo	5 mg/kg every 12 hrs	2 days
	Children aged $\geq 1$ mo	10 mg/kg every 12 hrs	2 days
	Adults	600 mg every 12 hrs	2 days
Ciprofloxacin <sup>§</sup>	Adults	500 mg	Single dose
Ceftriaxone	Children age <15 yrs	125 mg	Single IM dose
Ceftriaxone	Adults	250 mg	Single IM dose

**Abbreviation:** IM = intramuscular.

\* Oral administration unless indicated otherwise.

<sup>†</sup> Rifampin is not recommended for pregnant women because the drug is teratogenic in laboratory animals. Because the reliability of oral contraceptives might be affected by rifampin therapy, consideration should be given to using alternative contraceptive measures while rifampin is being administered.

<sup>§</sup> Ciprofloxacin is not generally recommended for persons aged <18 years or for pregnant and lactating women because the drug causes cartilage damage for immature laboratory animals. However, ciprofloxacin may be used for chemoprophylaxis of children when no acceptable alternative therapy is available. A recent review identified no reports of irreversible cartilage toxicity or age-associated adverse events in children and adolescents (Source: Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? *Clin Infect Dis* 2002;35:S191–9).

## References

1. De Wals P, Hertoghe, L, Borlee-Grimee I, et al. Meningococcal disease in Belgium, secondary attack rate among household, day-care nursery and preelementary school contacts. *J Infect* 1981;3(Suppl 1):53–61.
2. Jacobson JA FG, Holloway JT. Meningococcal disease in day-care centers. *Pediatrics* 1977;59:299–300.
3. CDC. Exposure to patients with meningococcal disease on aircrafts—United States, 1999–2001. *MMWR* 2001;50:485–9.
4. Anonymous. Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974. *JAMA* 1976;235:261–5.
5. Gilmore A, Stuart J, Andrews N. Risk of secondary meningococcal disease in health-care workers. *The Lancet* 2000;356(9242):1654–5.
6. Winstead JM, McKinsey DS, Tasker S, De Groote MA, Baddour LM. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. *Clin Infect Dis* 2000;30:87–94.
7. Barquet N, Gasser I, Domingo P, Moraga FA, Macaya A, Elcuaz R. Primary meningococcal conjunctivitis: report of 21 patients and review. *Rev Infect Dis* 1990;12:838–47.
8. Stansfield RE, Masterton RG, Dale BA, Fallon RJ. Primary meningococcal conjunctivitis and the need for prophylaxis in close contacts. *J Infect* 1994;29:211–4.
9. Dworzack DL, Sanders CC, Horowitz EA, et al. Evaluation of single-dose ciprofloxacin in the eradication of *Neisseria meningitidis* from nasopharyngeal carriers. *Antimicrob Agents Chem* 1988;32:1740–1.
10. Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampin in eradicating pharyngeal carriage of group A *Neisseria meningitidis*. *Lancet* 1988;2:1239–42.
11. Gaunt P, Lambert B. Single dose ciprofloxacin for the eradication of pharyngeal carriage of *Neisseria meningitidis*. *J Antimicrob Chem* 1988;21:489–96.
12. Broome CV. The carrier state: *Neisseria meningitidis*. *J Antimicrob Chem* 1986;18 (Suppl A):25–34.
13. Abramson JS SJ. Persistence of *Neisseria meningitidis* in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease. *J Infect Dis* 1985;151:370–1.
14. Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by *Neisseria meningitidis*. *Pediatr Infect Dis J* 1998;17:816–9.
15. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-resistant *Neisseria meningitidis* in North America. *N Engl J Med* 2009;360:886–92.

## APPENDIX B

### Evaluation and Management of Suspected Outbreaks of Meningococcal Disease

As routine vaccination coverage among adolescents with MenACWY increases, the number of serogroup C and Y has declined (CDC, unpublished data, 2012). However, outbreaks might occur in age groups that are not routinely recommended to be vaccinated with MenACWY and deaths caused by meningococcal outbreaks can result in high levels of anxiety in a community (1). Mass vaccination might play a role protecting the population at risk during an outbreak. The decision to implement a mass vaccination campaign to prevent meningococcal disease depends on whether the occurrence of more than one case represents an outbreak or an unusual clustering of endemic disease. Because the number of cases in outbreaks is usually not substantial, this determination often requires evaluation and analysis of the patterns of disease occurrence. Mass vaccination campaigns are expensive, require a massive public health effort, and can create unwarranted concern among the public. However, mass vaccination campaigns might offer an opportunity to increase coverage in otherwise hard-to-reach populations (e.g., adolescents who have dropped out of school).

#### Population at Risk: Organization- and Community-Based Outbreaks

In addition to close contacts, persons considered to be at increased risk for meningococcal disease compared with historic rates of disease in the same population in the general U.S. population are classified as being at risk. The population at risk is used as the denominator in calculations of the disease attack rate. The population at risk is usually defined on the basis of organizational affiliation or community of residence. In organization-based outbreaks, cases are linked by a common affiliation other than a shared, geographically delineated community; the population at risk is thus usually the group of persons who best represent that affiliation. For example, if the only association between patients is attending the same school or university, the population at risk is all persons attending the school or university. In community-based outbreaks, patients have no common affiliation other than a shared, geographically defined community. The population at risk can be defined as the smallest geographically contiguous population that includes all (or nearly all) patients. This population is usually a neighborhood, town, city, or county whose size is obtained from census data.

Distinguishing whether an outbreak should be classified as organization- or community-based is complicated by the fact that, in certain instances, these types of outbreaks occur simultaneously. Calculation of attack rates for

organization-based outbreaks is most useful for large organizations (e.g., universities). However, in the majority of organization-based outbreaks with three or even two cases of disease, the rate will be >10 cases/100,000 population. In such situations, public health officials also might consider vaccination after only two primary cases are identified.

#### Attack Rate and Decision to Vaccinate

For a primary attack rate to be calculated, all confirmed cases (Box) of the same serogroup should be summed; secondary cases should be excluded and each set of coprimary cases counted as one case. Because attack rates are calculated both to characterize the risk for disease among the general population and to determine whether overall rates have increased, related cases (secondary and coprimary) should not be included.

If three or more cases have occurred in either an organization- or a community-based outbreak during  $\leq 3$  months (starting at the time of the first confirmed or probable case), a primary attack rate should be calculated. Rate calculations should not be annualized. The following formula is used to calculate attack rates:

Attack rate per 100,000 = [(number of primary confirmed or probable cases during a 3-month period) / (number of population at risk)] x 100,000.

Vaccination of the population at risk should be considered if the attack rate is >10 cases/100,000 persons. Public health personnel should consider the following factors: 1) completeness of case reporting and number of possible cases of meningococcal disease for which bacteriologic confirmation or serogroup data are not available; 2) occurrence of additional cases of meningococcal disease after recognition of a suspected outbreak (e.g., if the outbreak occurred 2 months previously and if no additional cases have occurred, in which case vaccination might be unlikely to prevent additional cases of meningococcal disease); and 3) logistic and financial considerations. Because available vaccines are not effective against *Neisseria meningitidis* serogroup B, vaccination should not be considered during serogroup B outbreaks.

#### Vaccination Group

Those persons designated to be administered vaccine during a vaccination campaign comprise a vaccination group. The vaccination group usually includes either the whole or a subset of the population of risk. Because meningococcal disease outbreak cases occur predominantly among persons aged <30 years (2), the vaccination group usually is that portion of the population at risk aged <30 years.

## BOX. Meningococcal disease case definitions\*

- **Confirmed case.** A confirmed case of meningococcal disease is one that is defined by isolation of *Neisseria meningitidis* from a normally sterile site (e.g., blood or cerebrospinal fluid) from a person with clinically compatible illness.
- **Probable case.** A probable case of meningococcal disease is one that is defined by detection of polysaccharide antigen or nucleic acid in cerebrospinal fluid (e.g., by latex agglutination, polymerase chain reaction, or immunohistochemistry) or the presence of clinical purpura fulminans in the absence of diagnostic culture from a person with clinically compatible illness.
- **Primary case.** A primary case of meningococcal disease is one that occurs in the absence of previous known close contact with another patient.
- **Secondary case.** A secondary case of meningococcal disease is one that occurs among close contacts of a primary patient >24 hours after onset of illness in the primary patient.
- **Coprietary cases.** Coprietary cases are two or more cases that occur among a group of close contacts with onset of illness separated by ≤24 hours.
- **Close contacts.** Close contacts of a patient who has meningococcal disease include 1) household members; 2) child-care center contacts; and 3) persons directly exposed to the patient's oral secretions (e.g., by kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management).

\* Source: Council of State and Territorial Epidemiologists position statement (available at <http://www.cste.org/ps2009/09-id-42.pdf>).

In the majority of organization-based outbreaks, the vaccination group includes the whole population at risk. In certain organization-based outbreaks, a vaccination group larger than the population at risk might be designated. For example, in a high school in which all outbreak-associated cases occurred among students, authorities might decide to offer vaccine to staff. In community-based outbreaks, the vaccination group usually can be defined as a subset of the population at risk (e.g., persons aged <30 years). In rare situations (e.g., in a town with a limited population) in which multiple cases have occurred among adults aged >29 years, the entire population might be considered for vaccination. For more substantial populations, this decision would be costly in terms of finances and human resources, and restricting the vaccination group to the persons in age groups with the highest attack rates might be more appropriate. Age-specific attack rates can be calculated by using the formula previously provided and by restricting the numerator and denominator to persons within specific age groups (e.g., persons aged <30 years).

Genotyping of *N. meningitidis* Isolates

Genotyping of *N. meningitidis* isolates by using such methods as pulsed-field gel electrophoresis or multilocus sequence analysis (MLST) might provide useful information for determining whether a group of cases represents an outbreak (3). Outbreaks of meningococcal disease usually are caused by closely related strains. Genotyping data can allow identification of an outbreak strain and help to better define the extent of the outbreak. If strains from a group of patients are unrelated by genotyping, the group of cases most likely does not represent an outbreak. Because molecular subtyping testing might not be readily available or accessible, initiation of outbreak-control efforts should not be delayed until genotyping results are available.

## Other Control Measures

Mass chemoprophylaxis (i.e., administration of antibiotics to substantial populations) is not recommended to control large outbreaks of disease. Disadvantages of mass chemoprophylaxis include cost of the drug and administration, difficulty of ensuring simultaneous administration of drugs to substantial populations, drug side effects, and emergence of resistant organisms. In addition, multiple sources and prolonged risk for exposure make this approach impractical and unlikely to succeed. In the majority of outbreak settings, these disadvantages outweigh the possible benefit in disease prevention. However, in outbreaks involving limited populations (e.g., an outbreak in a single school), administration of chemoprophylaxis might be considered (4), especially in serogroup B outbreaks, for which available vaccines are not effective (5). When making a decision about initiating mass chemoprophylaxis in these settings, public health officials should consider not only the potential for prevention of new cases but also the logistics, cost, and potential for developing antimicrobial resistance (6,7). If mass chemoprophylaxis is undertaken, it should be administered to all targeted persons at the same time. In the United States, measures that have not been recommended for control of meningococcal disease outbreaks include restricting travel to areas with an outbreak, closing schools or universities, or canceling sporting or social events.

Educating communities, physicians, and other health-care personnel about meningococcal disease to promote an early case recognition and early care-seeking behaviors is an important part of managing suspected meningococcal disease outbreaks. Education efforts should be initiated as soon as an outbreak of meningococcal disease is suspected (7). Information about the signs and symptoms of meningococcal disease is available at <http://www.cdc.gov/meningococcal/about/symptoms.html>.



## References

1. Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE. Increased case-fatality rate associated with outbreaks of *Neisseria meningitidis* infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. *Clin Infect Dis* 2006;43:49–54.
2. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. *JAMA* 1995;273:383–9.
3. Popovic T, Schmink S, Rosenstein NA, et al. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by *Neisseria meningitidis* serogroup C. *J Clin Microbiol* 2001;39:75–85.
4. Zangwill KM, Schuchat A, Riedo FX, et al. School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. *JAMA* 1997;277:389–95.
5. Jackson LA, Alexander ER, DeBolt CA, et al. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease. *Pediatr Infect Dis J* 1996;15:992–8.
6. Nelson JD MG. The *Pediatr Infect Dis J* Newsletter. *Pediatr Infect Dis J* 1997:16.
7. CDC. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-5):13–21.

## ACIP Membership List As of June 2012

**Chair:** Carol Baker, MD, Baylor College of Medicine, Houston, Texas.

**Executive Secretary:** Larry Pickering, MD, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.

**Members:** Nancy Bennett, MD, University of Rochester School of Medicine and Dentistry, Rochester, New York; Joseph Bocchini, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana; Douglas Campos-Outcalt, MD, University of Arizona College of Medicine, Phoenix, Arizona; Tamera Coyne-Beasley, MD, University of North Carolina, Chapel Hill, North Carolina; Jeffrey Duchin, MD, University of Washington, Seattle, Washington; Kristen Ehresmann, MPH, Minnesota Department of Health, St. Paul, Minnesota; Renée Jenkins, MD, Howard University School of Medicine, District of Columbia; Wendy Keitel, MD, Baylor College of Medicine, Houston, Texas; Michael Marcy, MD, UCLA Center for Vaccine Research, Torrance, California; Cody Meissner, MD, Tufts Medical Center, Boston, Massachusetts; Sara Rosenbaum, JD, Georgetown University, District of Columbia; Mark Sawyer, MD, University of California at San Diego, California; Jonathan Temte, MD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Marietta Vázquez, MD, Yale University School of Medicine, New Haven, Connecticut.

**Ex Officio Members:** Geoffrey S. Evans, MD, Health Resources and Services Administration, Rockville, Maryland; Jesse Geibe, MD, Department of Defense, CDC, Atlanta, Georgia; Bruce Gellin, MD, National Vaccine Program Office, District of Columbia; Richard Gorman, MD, National Institutes of Health, Bethesda, Maryland; Amy Groom, MPH, Indian Health Service, Albuquerque, New Mexico; Mary Beth Hance, Centers for Medicare and Medicaid Services, Baltimore, Maryland; Linda Kinsinger, MD, Department of Veterans Affairs, Durham, North Carolina; Wellington Sun, MD, Food and Drug Administration, Bethesda, Maryland.

**Liaison Representatives:** American Academy of Family Physicians, Jamie Loehr, MD, Ithaca, New York; American Academy of Pediatrics, Michael Brady, MD, Columbus, Ohio; David Kimberlin, MD, Birmingham, Alabama; American Academy of Physician Assistants, Marie-Michèle Léger, MPH, Alexandria, Virginia; American College Health Association, James C. Turner, MD, Charlottesville, Virginia; American College of Obstetricians and Gynecologists, Laura Riley, MD, Boston, Massachusetts; American College of Physicians, Gregory Poland, MD, Rochester, Minnesota; American Geriatrics Society, Kenneth Schmader, MD, Durham, North Carolina; America's Health Insurance Plans, Mark Netoskie, MD, Houston, Texas; American Medical Association, Litjen Tan, PhD, Chicago, Illinois; American Nurses Association, Katie Brewer, MSN, Silver Springs, Maryland; American Osteopathic Association, Stanley Grogg, DO, Tulsa, Oklahoma; American Pharmacists Association, Stephan L. Foster, PharmD, Memphis, Tennessee; Association of Immunization Managers, Kelly Moore, MD, Nashville, Tennessee; Association for Prevention Teaching and Research, W. Paul McKinney, MD, Louisville, Kentucky; Association of State and Territorial Health Officials, José Montero, MD, Concord, New Hampshire; Biotechnology Industry Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee on Immunization, Bryna Warshawsky, MDCM, Ontario, Canada; Council of State and Territorial Epidemiologists, Christine Hahn, MD, Boise, Idaho; Department of Health, United Kingdom, David M. Salisbury, MD, London, United Kingdom; Healthcare Infection Control Practices Advisory Committee, Alexis Elward, MD, St. Louis, Missouri; Infectious Diseases Society of America, Kathleen Neuzil, MD, Seattle, Washington; National Association of County and City Health Officials, Matthew Zahn, MD, Louisville, Kentucky; National Association of Pediatric Nurse Practitioners, Patricia Stinchfield, MPH, St. Paul, Minnesota; National Foundation for Infectious Diseases, William Schaffner, MD, Nashville, Tennessee; National Immunization Council and Child Health Program, Mexico, Vesta Richardson, MD, Mexico City, Mexico; National Medical Association, Patricia Whitley-Williams, MD, New Brunswick, New Jersey; National Vaccine Advisory Committee, Walter Orenstein, MD, Atlanta, Georgia; Pharmaceutical Research and Manufacturers of America, Damian A. Braga, Swiftwater, Pennsylvania; Society for Adolescent Health and Medicine, Amy Middleman, MD, Houston, Texas; Society for Healthcare Epidemiology of America, Harry Keyserling, MD, Atlanta, Georgia.

## Meningococcal Vaccines Work Group

**Chair:** Lorry Rubin, MD, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York.

**Members:** Carol Baker, MD, Baylor College of Medicine, Houston, Texas; Michael Brady, MD, Ohio State University, Columbus, Ohio; Douglas Campos-Outcalt, MD, University of Arizona College of Medicine, Phoenix, Arizona; Richard Clover, MD, University of Louisville School of Public Health, Louisville, Kentucky; Kristen Ehresmann, MPH, Minnesota Department of Health, St. Paul, Minnesota; Lucia Lee, MD, Food and Drug Administration, Rockville, Maryland; Martin Luta, MD, Delaware Division of Public Health, Dover, Delaware; Michael Marcy, MD, UCLA Center for Vaccine Research, Torrance, California; W. Paul McKinney, MD, Association for Prevention Teaching and Research, Louisville, Kentucky; Cody Meissner, MD, Tufts University School of Medicine, Boston, Massachusetts; Amy Middleman, MD, Society for Adolescent Health and Medicine, Houston, Texas; Karen O'Brien, MD, US Army Training and Doctrine Command, Fort Monroe, Virginia; Paul Offit, MD, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Georges Peter, MD, Rhode Island Hospital, Providence, Rhode Island; William Schaffner, MD, National Foundation for Infectious Diseases, Nashville, Tennessee; David Stephens, MD, Emory University School of Medicine, Atlanta, Georgia; James C. Turner, MD, American College Health Association, Charlottesville, Virginia; Marietta Vázquez, MD, Yale University School of Medicine, New Haven, Connecticut.

**Contributors:** William Atkinson, MD; Elizabeth Briere, MD; Thomas Clark, MD; Jonathan Duffy, MD; Jessica MacNeil, MPH; Nancy E. Messonnier, MD; Ismael R. Ortega-Sanchez, PhD; Shannon Stokley, MPH, CDC, Atlanta, Georgia.

**Secretariat (CDC):** Amanda C. Cohn, MD, CDC, Atlanta, Georgia.



The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit MMWR's free subscription page at <http://www.cdc.gov/mmwr/mmwrsubscribe.html>. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to [mmwrq@cdc.gov](mailto:mmwrq@cdc.gov).

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 1057-5987